Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
29 "Non-alcoholic fatty liver"
Filter
Filter
Article type
Keywords
Publication year
Authors
Funded articles
Brief Reports
Characteristics of Metabolic Dysfunction-Associated Steatotic Liver Disease and Its Risk for Hepatic Fibrosis in 476,124 Korean Adults: A Cross-Sectional Study
Da Yeon Lee, Ji-Hee Ko, Han-Na Jang, Sun Joon Moon, Hye-Mi Kwon, Se Eun Park, Cheol-Young Park, Won-Young Lee, Ki-Won Oh, Eun-Jung Rhee
Received December 16, 2024  Accepted February 3, 2025  Published online March 27, 2025  
DOI: https://doi.org/10.3803/EnM.2024.2281    [Epub ahead of print]
  • 374 View
  • 19 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
As the new terminology of metabolic dysfunction-associated steatotic liver disease (MASLD) and MASLD with increased alcohol intake (MetALD) has emerged, the clinical significance of MASLD is increasing. This cross-sectional study analyzed 476,124 health checkup participants (2002–2022) to compare hepatic fibrosis risks across MASLD, MetALD, non-alcoholic fatty liver disease (NAFLD), and metabolic dysfunction-associated fatty liver disease (MAFLD). Steatotic liver was identified via ultrasonography, and fibrosis risk was assessed using aspartate aminotransferase to platelet ratio index and NAFLD fibrosis score. The prevalence of NAFLD, MAFLD, MASLD, and MetALD was 30.1%, 32.3%, 29.8%, and 3.0%, respectively, with a 27.9% overlap among three conditions. Participants with steatotic liver were predominantly male, with higher glucose, lipids, liver enzymes, and homeostasis model assessment of insulin resistance levels. Three disease definitions largely overlapped, with MASLD and NAFLD being very similar, while participants with MAFLD and MetALD showed increased fibrosis risk (clinical trial registration number: 2024-11-050).
Close layer
Diabetes, obesity and metabolism
Performance of Simple Fibrosis Score in Non-Alcoholic Fatty Liver Disease with and without Type 2 Diabetes
Seung Min Chung, Min Kyu Kang, Jun Sung Moon, Jung Gil Park
Endocrinol Metab. 2023;38(2):277-281.   Published online March 13, 2023
DOI: https://doi.org/10.3803/EnM.2022.1635
  • 3,942 View
  • 127 Download
  • 5 Web of Science
  • 6 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
This cross-sectional study enrolled 267 patients with metabolic risk factors and established non-alcoholic fatty liver disease in the prospective cohort. The performance of fibrosis-4 (FIB-4) score (≥1.3) to diagnose advanced fibrosis using transient elastography (liver stiffness measurement [LSM] ≥8 kPa) was analyzed. Comparing patients with type 2 diabetes (T2D, n=87) and without (n=180), not FIB-4, but LSM was significantly higher in T2D (P=0.026). The prevalence of advanced fibrosis was 17.2% in T2D and 12.8% in non-T2D. FIB-4 exhibited higher proportion of false negatives in T2D patients (10.9%) than those without (5.2%). The diagnostic performance of FIB-4 was suboptimal in T2D (area under curve [AUC], 0.653; 95% confidence interval [CI], 0.462 to 0.844) compared to that in non-T2D (AUC, 0.826; 95% CI, 0.724 to 0.927). In conclusion, patients with T2D might be beneficial to conduct transient elastography without screening to avoid missing advanced fibrosis.

Citations

Citations to this article as recorded by  
  • The effect of semaglutide combined with metformin on liver inflammation and pancreatic beta-cell function in patients with type 2 diabetes and non-alcoholic fatty liver disease
    Rong Ren, Yanxia Pei, Lufei Kong, Yixin Shi
    Journal of Diabetes and its Complications.2025; 39(2): 108932.     CrossRef
  • Metabolic-Associated Steatotic Liver Disease (MASLD) and Type 2 Diabetes: Mechanisms, Diagnostic Approaches, and Therapeutic Interventions
    Anastasia Ntikoudi, Anastasia Papachristou, Afroditi Tsalkitzi, Nikoletta Margari, Eleni Evangelou, Eugenia Vlachou
    Diabetology.2025; 6(4): 23.     CrossRef
  • Multiple Definitions of Fatty Liver Disease: Which One Most Accurately Predicts Diabetes?
    Eun-Jung Rhee
    Endocrinology and Metabolism.2024; 39(2): 397.     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction–associated steatotic liver disease
    Xiaolong Qi, Jie Li, Cyrielle Caussy, Gao-Jun Teng, Rohit Loomba
    Hepatology.2024;[Epub]     CrossRef
  • Prevalence of High and Moderate Risk of Liver Fibrosis Among Patients With Diabetes at a Noncommunicable Diseases (NCD) Clinic in a Primary Healthcare Center in Northern India
    Anubhav Mondal, Aninda Debnath, Ghurumourthy Dhandapani, Abhishek Sharma, Shveta Lukhmana, Geeta Yadav
    Cureus.2023;[Epub]     CrossRef
Close layer
Original Article
Diabetes, Obesity and Metabolism
The Impact of Insulin Resistance on Hepatic Fibrosis among United States Adults with Non-Alcoholic Fatty Liver Disease: NHANES 2017 to 2018
Ji Cheol Bae, Lauren A. Beste, Kristina M. Utzschneider
Endocrinol Metab. 2022;37(3):455-465.   Published online June 21, 2022
DOI: https://doi.org/10.3803/EnM.2022.1434
  • 6,776 View
  • 160 Download
  • 17 Web of Science
  • 17 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
We aimed to investigate the association of hepatic steatosis with liver fibrosis and to assess the interactive effects of hepatic steatosis and insulin resistance on liver fibrosis in a nationally representative sample of United States adults.
Methods
We conducted a cross-sectional analysis using data from National Health and Nutrition Examination Survey 2017 to 2018, which for the first time included transient elastography to assess liver stiffness and hepatic steatosis. We evaluated the association between hepatic steatosis (using controlled attenuation parameter [CAP]) and clinically significant liver fibrosis (defined as liver stiffness ≥7.5 kPa) using logistic regression with an interaction term for hepatic steatosis and insulin resistance (defined as homeostatic model assessment of insulin resistance ≥3.0).
Results
Among adults undergoing transient elastography (n=2,023), 45.9% had moderate or greater hepatic steatosis and 11.3% had clinically significant liver fibrosis. After adjustment for demographic and metabolic factors, the odds of significant liver fibrosis increased as CAP score rose (odds ratio, 1.35 per standard deviation increment; 95% confidence interval, 1.11 to 1.64). We detected a significant interaction effect between CAP score and insulin resistance on the probability of significant liver fibrosis (P=0.016 for interaction). The probability of significant liver fibrosis increased in the presence of insulin resistance with increasing CAP score, while those without insulin resistance had low probability of significant liver fibrosis, even with high CAP scores.
Conclusion
Individuals with hepatic steatosis had higher odds of fibrosis when insulin resistance was present. Our findings emphasize the importance of the metabolic aspects of the disease on fibrosis risk and suggest a need to better identify patients with metabolic associated fatty liver disease.

Citations

Citations to this article as recorded by  
  • Appendicular skeletal muscle mass is associated with metabolic dysfunction-associated steatotic liver disease severity in young men: a cross-sectional and longitudinal study
    Jaejun Lee, Jinson So, Chang In Han, Hyun Yang, Pil Soo Sung, Si Hyun Bae, Do Seon Song
    Hepatology International.2025; 19(1): 181.     CrossRef
  • Association between the triglyceride-glucose index and liver fibrosis in adults with metabolism-related fatty liver disease in the United States: a cross-sectional study of NHANES 2017–2020
    Yuou Ying, Yuan Ji, Ruyi Ju, Jinhan Chen, Mingxian Chen
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • The Value of TyG‐Related Indices in Evaluating MASLD and Significant Liver Fibrosis in MASLD
    Haoxuan Zou, Jiejie Xie, Xiaopu Ma, Yan Xie, Xingshun Qi
    Canadian Journal of Gastroenterology and Hepatology.2025;[Epub]     CrossRef
  • Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma
    Toru Nakamura, Atsutaka Masuda, Dan Nakano, Keisuke Amano, Tomoya Sano, Masahito Nakano, Takumi Kawaguchi
    Cells.2025; 14(6): 428.     CrossRef
  • Association of insulin resistance indicators with hepatic steatosis and fibrosis in patients with metabolic syndrome
    Tzu-chia Kuo, Yang-bor Lu, Chieh-lun Yang, Bin Wang, Lin-xin Chen, Ching-ping Su
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • No More NAFLD: The Term Is Now MASLD
    Ji Cheol Bae
    Endocrinology and Metabolism.2024; 39(1): 92.     CrossRef
  • Insulin Resistance/Sensitivity Measures as Screening Indicators of Metabolic-Associated Fatty Liver Disease and Liver Fibrosis
    Mohammad E. Khamseh, Mojtaba Malek, Soodeh Jahangiri, Sohrab Nobarani, Azita Hekmatdoost, Marieh Salavatizadeh, Samira Soltanieh, Haleh Chehrehgosha, Hoda Taheri, Zeinab Montazeri, Fereshteh Attaran, Faramarz Ismail-Beigi, Fariba Alaei-Shahmiri
    Digestive Diseases and Sciences.2024; 69(4): 1430.     CrossRef
  • The association of Neuromedin U levels and non-alcoholic fatty liver disease: A comparative analysis
    Murat Keskin, Sercan Avul, Aylin Beyaz, Nizameddin Koca
    Heliyon.2024; 10(5): e27291.     CrossRef
  • Oral Insulin Alleviates Liver Fibrosis and Reduces Liver Steatosis in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes: Results of Phase II Randomized, Placebo-controlled Feasibility Clinical Trial
    Yuval Ishay, Joel Neutel, Yotam Kolben, Ram Gelman, Orly Sneh Arbib, Oliver Lopez, Helena Katchman, Rizwana Mohseni, Miriam Kidron, Yaron Ilan
    Gastro Hep Advances.2024; 3(3): 417.     CrossRef
  • Comparative and Predictive Significance of Serum Leptin Levels in Non-alcoholic Fatty Liver Disease
    Mehwish Qamar, Abeer Fatima, Ambreen Tauseef, Muhammad I Yousufzai, Ibrahim Liaqat, Qanbar Naqvi
    Cureus.2024;[Epub]     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtyping
    Shahid Habib
    World Journal of Gastrointestinal Pathophysiology.2024;[Epub]     CrossRef
  • Greater Severity of Steatosis Is Associated with a Higher Risk of Incident Diabetes: A Retrospective Longitudinal Study
    Ji Min Han, Jung Hwan Cho, Hye In Kim, Sunghwan Suh, Yu-Ji Lee, Jung Won Lee, Kwang Min Kim, Ji Cheol Bae
    Endocrinology and Metabolism.2023; 38(4): 418.     CrossRef
  • Hepatic T-cell senescence and exhaustion are implicated in the progression of fatty liver disease in patients with type 2 diabetes and mouse model with nonalcoholic steatohepatitis
    Byeong Chang Sim, Yea Eun Kang, Sun Kyoung You, Seong Eun Lee, Ha Thi Nga, Ho Yeop Lee, Thi Linh Nguyen, Ji Sun Moon, Jingwen Tian, Hyo Ju Jang, Jeong Eun Lee, Hyon-Seung Yi
    Cell Death & Disease.2023;[Epub]     CrossRef
  • Familial clustering of nonalcoholic fatty liver disease in first‐degree relatives of adults with lean nonalcoholic fatty liver disease
    Sorachat Niltwat, Chanin Limwongse, Natthinee Charatcharoenwitthaya, Duangkamon Bunditvorapoom, Wimolrak Bandidniyamanon, Phunchai Charatcharoenwitthaya
    Liver International.2023; 43(12): 2713.     CrossRef
  • Metabolic Score for Insulin Resistance Is Inversely Related to Incident Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
    Jun-Hyuk Lee, Yu-Jin Kwon, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
    Nutrients.2022; 14(15): 3039.     CrossRef
  • DPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once?
    Ji Cheol Bae
    Endocrinology and Metabolism.2022; 37(6): 858.     CrossRef
Close layer
Review Article
Diabetes, Obesity and Metabolism
State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
Yongin Cho, Yong-ho Lee
Endocrinol Metab. 2022;37(1):38-52.   Published online February 28, 2022
DOI: https://doi.org/10.3803/EnM.2022.102
  • 6,441 View
  • 304 Download
  • 4 Web of Science
  • 4 Crossref
AbstractAbstract PDFPubReader   ePub   
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, and non-alcoholic steatohepatitis (NASH), a subtype of NAFLD, can progress to cirrhosis, hepatocellular carcinoma, and death. Nevertheless, the current treatment for NAFLD/NASH is limited to lifestyle modifications, and no drugs are currently officially approved as treatments for NASH. Many global pharmaceutical companies are pursuing the development of medications for the treatment of NASH, and results from phase 2 and 3 clinical trials have been published in recent years. Here, we review data from these recent clinical trials and reports on the efficacy of newly developed antidiabetic drugs in NASH treatment.

Citations

Citations to this article as recorded by  
  • Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
    Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
    BMJ.2024; : e076388.     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Soyeon Shin, Jaeyoung Kim, Ju Yeon Lee, Jun Kim, Chang-Myung Oh
    Journal of Obesity & Metabolic Syndrome.2023; 32(4): 289.     CrossRef
  • Sodium-glucose cotransporter 2 inhibitors for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: A nationwide propensity-score matched cohort study
    Jinyoung Kim, Kyungdo Han, Bongsung Kim, Ki-Hyun Baek, Ki-Ho Song, Mee Kyoung Kim, Hyuk-Sang Kwon
    Diabetes Research and Clinical Practice.2022; 194: 110187.     CrossRef
Close layer
Original Articles
Diabetes, Obesity and Metabolism
Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway
Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
Endocrinol Metab. 2022;37(1):74-83.   Published online February 9, 2022
DOI: https://doi.org/10.3803/EnM.2021.1293
  • 7,316 View
  • 267 Download
  • 11 Web of Science
  • 12 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Dulaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA), has been shown to reduce body weight and liver fat content in patients with type 2 diabetes. Family with sequence similarity 3 member A (FAM3A) plays a vital role in regulating glucose and lipid metabolism. The aim of this study was to determine the mechanisms by which dulaglutide protects against hepatic steatosis in HepG2 cells treated with palmitic acid (PA).
Methods
HepG2 cells were pretreated with 400 μM PA for 24 hours, followed by treatment with or without 100 nM dulaglutide for 24 hours. Hepatic lipid accumulation was determined using Oil red O staining and triglyceride (TG) assay, and the expression of lipid metabolism-associated factor was analyzed using quantitative real time polymerase chain reaction and Western blotting.
Results
Dulaglutide significantly decreased hepatic lipid accumulation and reduced the expression of genes associated with lipid droplet binding proteins, de novo lipogenesis, and TG synthesis in PA-treated HepG2 cells. Dulaglutide also increased the expression of proteins associated with lipolysis and fatty acid oxidation and FAM3A in PA-treated cells. However, exendin-(9-39), a GLP-1R antagonist, reversed the expression of FAM3A, and fatty acid oxidation-associated factors increased due to dulaglutide. In addition, inhibition of FAM3A by siRNA attenuated the reducing effect of dulaglutide on TG content and its increasing effect on regulation of fatty acid oxidation.
Conclusion
These results suggest that dulaglutide could be used therapeutically for improving nonalcoholic fatty liver disease, and its effect could be mediated in part via upregulation of FAM3A expression through a GLP-1R-dependent pathway.

Citations

Citations to this article as recorded by  
  • Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes
    Brandon Havranek, Rebecca Loh, Beatriz Torre, Rachel Redfield, Dina Halegoua-DeMarzio
    Scientific Reports.2025;[Epub]     CrossRef
  • Therapeutic effects and mechanisms of Xinmaitong formula for type 2 diabetes mellitus via GLP-1R signaling
    Weidong Pu, Yang Pan, Kang Yang, Jian Gao, Fen Tian, Jingrui Song, Yubing Huang, Yanmei Li
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD
    Haoran Jiang, Linquan Zang
    Current Pharmaceutical Design.2024; 30(2): 100.     CrossRef
  • Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
    Tong Bu, Ziyan Sun, Yi Pan, Xia Deng, Guoyue Yuan
    Diabetes & Metabolism Journal.2024; 48(3): 354.     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence
    Salvatore Corrao, Chiara Pollicino, Dalila Maggio, Alessandra Torres, Christiano Argano
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Effects of the switch from dulaglutide to tirzepatide on glycemic control, body weight, and fatty liver: a retrospective study
    Toshitaka Sawamura, Ren Mizoguchi, Ai Ohmori, Mitsuhiro Kometani, Takashi Yoneda, Shigehiro Karashima
    Journal of Diabetes & Metabolic Disorders.2024; 23(2): 2105.     CrossRef
  • FABP1 induces lipogenesis by regulating the processing of SREBP1 in hepatocytes of large yellow croaker (Larimichthys crocea)
    Fan Chen, Tingting Hao, Qiang Chen, Yuning Sun, Yanan Shen, Zengqi Zhao, Jianlong Du, Yueru Li, Kangsen Mai, Qinghui Ai
    The FASEB Journal.2024;[Epub]     CrossRef
  • GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
    Riccardo Nevola, Raffaella Epifani, Simona Imbriani, Giovanni Tortorella, Concetta Aprea, Raffaele Galiero, Luca Rinaldi, Raffaele Marfella, Ferdinando Carlo Sasso
    International Journal of Molecular Sciences.2023; 24(2): 1703.     CrossRef
  • FAM3A mediates the phenotypic switch of human aortic smooth muscle cells stimulated with oxidised low-density lipoprotein by influencing the PI3K-AKT pathway
    Lei Yang, Baoshun Du, Shitao Zhang, Maode Wang
    In Vitro Cellular & Developmental Biology - Animal.2023; 59(6): 431.     CrossRef
  • ATP Secretion and Metabolism in Regulating Pancreatic Beta Cell Functions and Hepatic Glycolipid Metabolism
    Jing Li, Han Yan, Rui Xiang, Weili Yang, Jingjing Ye, Ruili Yin, Jichun Yang, Yujing Chi
    Frontiers in Physiology.2022;[Epub]     CrossRef
  • Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
    Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, Shan Liu, Tatsunori Miyata, Qiaoling Song, Qingda Wei, Chenyang Zhao, Chunhua Lin, Jinbo Yang
    Signal Transduction and Targeted Therapy.2022;[Epub]     CrossRef
Close layer
Diabetes, Obesity and Metabolism
The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE−/−FXR−/− Mice
Yenna Lee, Bo-Rahm Kim, Geun-Hyung Kang, Gwan Jae Lee, Young Joo Park, Haeryoung Kim, Hak Chul Jang, Sung Hee Choi
Endocrinol Metab. 2021;36(6):1243-1253.   Published online December 28, 2021
DOI: https://doi.org/10.3803/EnM.2021.1100
  • 7,971 View
  • 177 Download
  • 17 Web of Science
  • 19 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Farnesoid X receptor (FXR), a bile acid–activated nuclear receptor, is a potent regulator of glucose and lipid metabolism as well as of bile acid metabolism. Previous studies have demonstrated that FXR deficiency is associated with metabolic derangements, including atherosclerosis and nonalcoholic fatty liver disease (NAFLD), but its mechanism remains unclear. In this study, we investigated the role of FXR in atherosclerosis and NAFLD and the effect of peroxisome proliferator-activated receptor (PPAR) agonists in mouse models with FXR deficiency.
Methods
En face lipid accumulation analysis, liver histology, serum levels of glucose and lipids, and mRNA expression of genes related to lipid metabolism were compared between apolipoprotein E (ApoE)−/− and ApoE−/−FXR−/− mice. The effects of PPARα and PPARγ agonists were also compared in both groups of mice.
Results
Compared with ApoE−/− mice, ApoE−/−FXR−/− mice showed more severe atherosclerosis, hepatic steatosis, and higher levels of serum cholesterol, low-density lipoprotein cholesterol, and triglycerides, accompanied by increased mRNA expression of FAS, ApoC2, TNFα, IL-6 (liver), ATGL, TGH, HSL, and MGL (adipocytes), and decreased mRNA expressions of CPT2 (liver) and Tfam (skeletal muscle). Treatment with a PPARα agonist, but not with a PPARγ agonist, partly reversed atherosclerosis and hepatic steatosis, and decreased plasma triglyceride levels in the ApoE−/−FXR−/− mice, in association with increased mRNA expression of CD36 and FATP and decreased expression of ApoC2 and ApoC3 (liver).
Conclusion
Loss of FXR is associated with aggravation of atherosclerosis and hepatic steatosis in ApoE-deficient mice, which could be reversed by a PPARα agonist through induction of fatty acid uptake, β-oxidation, and triglyceride hydrolysis.

Citations

Citations to this article as recorded by  
  • PCSK9 with a gain of function D374Y mutation aggravates atherosclerosis by inhibiting PPARα expression
    Yuan feng Cui, Xiao cui Chen, Tuoluonayi Mijiti, Abidan Abudurusuli, Li hui Deng, Xiang Ma, Bangdang Chen
    Scientific Reports.2025;[Epub]     CrossRef
  • Calycosin improves atherosclerosis by reshaping the interaction between the gut microbiome and bile acid metabolism
    Jiaqi Fu, Donghua Yu, Yuqin Liang, Xin Gao, Yunhe Shi, Yu Wang, Pingping Chen, Fang Lu, Shumin Liu
    Food Science and Human Wellness.2025; 14(4): 9250085.     CrossRef
  • Restoring FXR expression as a novel treatment strategy in liver cancer and other liver disorders
    Sosmitha Girisa, Babu Santha Aswani, Mukesh Kumar Manickasamy, Mangala Hegde, Mohammed S. Alqahtani, Mohamed Abbas, Gautam Sethi, Ajaikumar B. Kunnumakkara
    Expert Opinion on Therapeutic Targets.2025;[Epub]     CrossRef
  • Evaluation of the hepatotoxicity of Psoralea corylifolia L. based on a zebrafish model
    Shu-Yan Gao, Jing-Cheng Zhao, Qing Xia, Chen Sun, Maimaiti Aili, Ainiwaer Talifu, Shi-Xia Huo, Yun Zhang, Zhi-Jian Li
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
    Yuxiao Jiang, Lili Wu, Xiaopeng Zhu, Hua Bian, Xin Gao, Mingfeng Xia
    Lipids in Health and Disease.2024;[Epub]     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Unlocking therapeutic potential: exploring cross-talk among emerging nuclear receptors to combat metabolic dysfunction in steatotic liver disease
    Milton Boaheng Antwi, Ariann Jennings, Sander Lefere, Dorien Clarisse, Anja Geerts, Lindsey Devisscher, Karolien De Bosscher
    npj Metabolic Health and Disease.2024;[Epub]     CrossRef
  • Monomethyl Branched‐Chain Fatty Acids Suppress M1 Macrophage Polarization via FABP4/PPAR‐γ Signaling Pathway
    Yuan He, Yu Zhang, Shuang Zhu, Yuan‐fa Liu, Sha Liu, Yong‐jiang Xu
    Molecular Nutrition & Food Research.2024;[Epub]     CrossRef
  • COL6A6 Peptide Vaccine Alleviates Atherosclerosis through Inducing Immune Response and Regulating Lipid Metabolism in Apoe−/− Mice
    Dongmei Tang, Yan Liu, Rui Duan, Run Lin, Zhonghao Li, Xianyan Liu, Jingrong Huang, Ming Zhao
    Cells.2024; 13(18): 1589.     CrossRef
  • Mitochondrial carnitine palmitoyltransferase-II dysfunction: A possible novel mechanism for nonalcoholic fatty liver disease in hepatocarcinogenesis
    Min Yao, Ping Zhou, Yan-Yan Qin, Li Wang, Deng-Fu Yao
    World Journal of Gastroenterology.2023; 29(12): 1765.     CrossRef
  • Emerging Roles of Gut Microbial Modulation of Bile Acid Composition in the Etiology of Cardiovascular Diseases
    Tess Yntema, Debby P. Y. Koonen, Folkert Kuipers
    Nutrients.2023; 15(8): 1850.     CrossRef
  • The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
    Alexandra C. Finney, Sandeep Das, Dhananjay Kumar, M. Peyton McKinney, Bishuang Cai, Arif Yurdagul, Oren Rom
    Frontiers in Cardiovascular Medicine.2023;[Epub]     CrossRef
  • Targeting PPARs for therapy of atherosclerosis: A review
    Miao Miao, Xue Wang, Tian Liu, Yan-Jie Li, Wen-Qian Yu, Tong-Mei Yang, Shou-Dong Guo
    International Journal of Biological Macromolecules.2023; 242: 125008.     CrossRef
  • Cabernet sauvignon dry red wine ameliorates atherosclerosis in mice by regulating inflammation and endothelial function, activating AMPK phosphorylation, and modulating gut microbiota
    Xinlong Cheng, Xue Han, Liangfu Zhou, Yasai Sun, Qian Zhou, Xuan Lin, Zhe Gao, Jie Wang, Wen Zhao
    Food Research International.2023; 169: 112942.     CrossRef
  • Impacts of dietary lipids derived from animal or vegetable sources on healthy rats
    Mostafa M Dalal, Gamal M Edrees, Hanaa A Hassan, Mamdouh Abdel-Mogib, Mai Alaa El-Dein
    Egyptian Journal of Basic and Applied Sciences.2023; 10(1): 618.     CrossRef
  • Whey protein hydrolysate alleviated atherosclerosis and hepatic steatosis by regulating lipid metabolism in apoE-/- mice fed a Western diet
    Kai Wang, Zixin Fu, Xiaoyi Li, Hui Hong, Xin Zhan, Xiaohong Guo, Yongkang Luo, Yuqing Tan
    Food Research International.2022; 157: 111419.     CrossRef
  • Melatonin alleviates PM2.5‐induced glucose metabolism disorder and lipidome alteration by regulating endoplasmic reticulum stress
    Zhou Du, Junjie Hu, Lisen Lin, Qingqing Liang, Mengqi Sun, Zhiwei Sun, Junchao Duan
    Journal of Pineal Research.2022;[Epub]     CrossRef
  • Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
    Joon Ho Moon, Kyuho Kim, Sung Hee Choi
    Endocrinology and Metabolism.2022; 37(4): 575.     CrossRef
  • The role of the gut microbiota in health and cardiovascular diseases
    Lu Wang, Shiqi Wang, Qing Zhang, Chengqi He, Chenying Fu, Quan Wei
    Molecular Biomedicine.2022;[Epub]     CrossRef
Close layer
Review Article
Diabetes, Obesity and Metabolism
Serotonergic Regulation of Hepatic Energy Metabolism
Jiwon Park, Wooju Jeong, Chahyeon Yun, Hail Kim, Chang-Myung Oh
Endocrinol Metab. 2021;36(6):1151-1160.   Published online December 16, 2021
DOI: https://doi.org/10.3803/EnM.2021.1331
  • 8,536 View
  • 253 Download
  • 10 Web of Science
  • 10 Crossref
AbstractAbstract PDFPubReader   ePub   
The liver is a vital organ that regulates systemic energy metabolism and many physiological functions. Nonalcoholic fatty liver disease (NAFLD) is the commonest cause of chronic liver disease and end-stage liver failure. NAFLD is primarily caused by metabolic disruption of lipid and glucose homeostasis. Serotonin (5-hydroxytryptamine [5-HT]) is a biogenic amine with several functions in both the central and peripheral systems. 5-HT functions as a neurotransmitter in the brain and a hormone in peripheral tissues to regulate systemic energy homeostasis. Several recent studies have proposed various roles of 5-HT in hepatic metabolism and inflammation using tissue-specific knockout mice and 5-HT-receptor agonists/antagonists. This review compiles the most recent research on the relationship between 5-HT and hepatic metabolism, and the role of 5-HT signaling as a potential therapeutic target in NAFLD.

Citations

Citations to this article as recorded by  
  • Maternal nutrient metabolism in the liver during pregnancy
    Hongxu Fang, Qingyang Li, Haichao Wang, Ying Ren, Leying Zhang, Ling Yang
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Neural Stem Cell-based Regenerative Therapy: A New Approach to Diabetes Treatment
    Kajal Sharma, Nidhi Puranik, Dhananjay Yadav
    Endocrine, Metabolic & Immune Disorders - Drug Targets.2024; 24(5): 531.     CrossRef
  • The Influence of BMP6 on Serotonin and Glucose Metabolism
    Marina Milešević, Ivona Matić Jelić, Viktorija Rumenović, Natalia Ivanjko, Slobodan Vukičević, Tatjana Bordukalo-Nikšić
    International Journal of Molecular Sciences.2024; 25(14): 7842.     CrossRef
  • Exploring Endogenous Tryptamines: Overlooked Agents Against Fibrosis in Chronic Disease? A Narrative Review
    Hunter W. Korsmo
    Livers.2024; 4(4): 615.     CrossRef
  • Metabolic and Molecular Response to High-Fat Diet Differs between Rats with Constitutionally High and Low Serotonin Tone
    Petra Baković, Maja Kesić, Darko Kolarić, Jasminka Štefulj, Lipa Čičin-Šain
    International Journal of Molecular Sciences.2023; 24(3): 2169.     CrossRef
  • Roles of gut microbes in metabolic-associated fatty liver disease
    Chun-Yao Chen, Han-Chen Ho
    Tzu Chi Medical Journal.2023;[Epub]     CrossRef
  • Imidazoles as Serotonin Receptor Modulators for Treatment of Depression: Structural Insights and Structure–Activity Relationship Studies
    Kapil Kumar Goel, Somesh Thapliyal, Rajeev Kharb, Gaurav Joshi, Arvind Negi, Bhupinder Kumar
    Pharmaceutics.2023; 15(9): 2208.     CrossRef
  • Serotonin in the regulation of systemic energy metabolism
    Joon Ho Moon, Chang‐Myung Oh, Hail Kim
    Journal of Diabetes Investigation.2022; 13(10): 1639.     CrossRef
  • Involvement of the liver-gut peripheral neural axis in nonalcoholic fatty liver disease pathologies via hepatic HTR2A
    Takashi Owaki, Kenya Kamimura, Masayoshi Ko, Itsuo Nagayama, Takuro Nagoya, Osamu Shibata, Chiyumi Oda, Shinichi Morita, Atsushi Kimura, Takeki Sato, Toru Setsu, Akira Sakamaki, Hiroteru Kamimura, Takeshi Yokoo, Shuji Terai
    Disease Models & Mechanisms.2022;[Epub]     CrossRef
  • Non-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines
    Anwesha Gangopadhyay, Radwa Ibrahim, Karli Theberge, Meghan May, Karen L. Houseknecht
    Frontiers in Neuroscience.2022;[Epub]     CrossRef
Close layer
Original Articles
Diabetes, Obesity and Metabolism
The Leg Fat to Total Fat Ratio Is Associated with Lower Risks of Non-Alcoholic Fatty Liver Disease and Less Severe Hepatic Fibrosis: Results from Nationwide Surveys (KNHANES 2008–2011)
Hyun Min Kim, Yong-ho Lee
Endocrinol Metab. 2021;36(6):1232-1242.   Published online November 23, 2021
DOI: https://doi.org/10.3803/EnM.2021.1087
  • 5,682 View
  • 147 Download
  • 7 Web of Science
  • 6 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The prevalence of non-alcoholic fatty liver disease (NAFLD) has rapidly increased worldwide. The aim of this study was to investigate whether there is an independent relationship between regional fat distribution, especially leg fat mass, and the presence of NAFLD using nationally representative data in Korea.
Methods
This cross-sectional study analyzed data from 14,502 participants in the Korea National Health and Nutrition Examination Survey 2008 to 2011. Total fat mass, leg fat mass, and appendicular skeletal muscle mass were measured by dual-energy X-ray absorptiometry. Validated NAFLD prediction models and scoring systems for hepatic fibrosis were used.
Results
The leg fat to total fat (LF/TF) ratio showed a negative relationship with many factors, including body mass index, waist circumference, blood pressure, fasting blood glucose, and liver enzyme levels. When the LF/TF ratio and indices of hepatic steatosis were stratified by quartiles, the LF/TF ratio showed a negative correlation with the scoring systems that were used. The LF/TF ratio showed better accuracy in predicting NAFLD than total fat mass or leg fat mass alone. After adjusting for various traditional and lifestyle factors, a low LF/TF ratio remained a risk factor for NAFLD. Among NAFLD subjects, the LF/TF ratio showed a negative relationship with hepatic fibrosis.
Conclusion
A lower LF/TF ratio was markedly associated with a higher risk of hepatic steatosis and advanced hepatic fibrosis using various predictive models in a Korean population. Therefore, the LF/TF ratio could be a useful anthropometric parameter to predict NAFLD or advanced hepatic fibrosis.

Citations

Citations to this article as recorded by  
  • Waistline to thigh circumference ratio as a predictor of MAFLD: a health care worker study with 2-year follow-up
    Xiaoyan Hao, Honghai He, Liyuan Tao, Wei Zhao, Peng Wang
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Regional fat distribution and hepatic fibrosis and steatosis severity in patients with nonalcoholic fatty liver disease and type 2 diabetes
    Asieh Mansour, Saeed Pourhassan, Hadis Gerami, Mohammad Reza Mohajeri‐Tehrani, Marziye Salahshour, Ali Abbasi, Elham Madreseh, Sayed Mahmoud Sajjadi‐Jazi
    Obesity Science & Practice.2024;[Epub]     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Adipose tissue insulin resistance index was inversely associated with gluteofemoral fat and skeletal muscle mass in Japanese women
    Satomi Minato-Inokawa, Mari Honda, Ayaka Tsuboi-Kaji, Mika Takeuchi, Kaori Kitaoka, Miki Kurata, Bin Wu, Tsutomu Kazumi, Keisuke Fukuo
    Scientific Reports.2024;[Epub]     CrossRef
  • A greater ratio of thigh subcutaneous fat to abdominal fat is associated with protection against non-alcoholic fatty liver disease
    Yebei Liang, Peizhu Chen, Siyu Chen, Dan Liu, Fusong Jiang, Zhijun Zhu, Keqing Dong, Li Wei, Xuhong Hou
    JHEP Reports.2023; 5(7): 100730.     CrossRef
  • Association between Alcohol Consumption and Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Alcohol Flushing Response in Men: The Korea National Health and Nutrition Examination Survey 2019–2021
    Dae Eon Kang, Si Nae Oh
    Nutrients.2023; 15(18): 3901.     CrossRef
Close layer
Diabetes, Obesity and Metabolism
Increased Risk of Nonalcoholic Fatty Liver Disease in Individuals with High Weight Variability
Inha Jung, Dae-Jeong Koo, Mi Yeon Lee, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
Endocrinol Metab. 2021;36(4):845-854.   Published online August 27, 2021
DOI: https://doi.org/10.3803/EnM.2021.1098
  • 6,794 View
  • 151 Download
  • 11 Web of Science
  • 12 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Weight loss through lifestyle modification is recommended for patients with nonalcoholic fatty liver disease (NAFLD). Recent studies have suggested that repeated loss and gain of weight is associated with worse health outcomes. This study aimed to examine the association between weight variability and the risk of NAFLD in patients without diabetes.
Methods
We examined the health-checkup data of 30,708 participants who had undergone serial examinations between 2010 and 2014. Weight variability was assessed using coefficient of variation and the average successive variability of weight (ASVW), which was defined as the sum of absolute weight changes between successive years over the 5-year period divided by 4. The participants were classified according to the baseline body mass index and weight difference over 4 years.
Results
On dividing the participants into four groups according to ASVW quartile groups, those in the highest quartile showed a significantly increased risk of NAFLD compared to those in the lowest quartile (odds ratio [OR], 1.89; 95% confidence interval [CI], 1.63 to 2.19). Among participants without obesity at baseline, individuals with high ASVW showed increased risk of NAFLD (OR, 1.80; 95% CI, 1.61 to 2.01). Participants with increased weight over 4 years and high ASVW demonstrated higher risk of NAFLD compared to those with stable weight and low ASVW (OR, 4.87; 95% CI, 4.29 to 5.53).
Conclusion
Regardless of participant baseline obesity status, high weight variability was associated with an increased risk of developing NAFLD. Our results suggest that further effort is required to minimize weight fluctuations after achieving a desirable body weight.

Citations

Citations to this article as recorded by  
  • Changes in Macronutrients during Dieting Lead to Weight Cycling and Metabolic Complications in Mouse Model
    Anouk Charlot, Anthony Bringolf, Léa Debrut, Joris Mallard, Anne-Laure Charles, Emilie Crouchet, Delphine Duteil, Bernard Geny, Joffrey Zoll
    Nutrients.2024; 16(5): 646.     CrossRef
  • Body weight variability and the risk of liver‐related outcomes in type 2 diabetes and steatotic liver disease: a cohort study
    Nathalie C. Leite, Claudia R. L. Cardoso, Cristiane A. Villela‐Nogueira, Gil F. Salles
    Obesity.2024; 32(6): 1210.     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • A machine-learned model for predicting weight loss success using weight change features early in treatment
    Farzad Shahabi, Samuel L. Battalio, Angela Fidler Pfammatter, Donald Hedeker, Bonnie Spring, Nabil Alshurafa
    npj Digital Medicine.2024;[Epub]     CrossRef
  • Long-Term Yo-Yo Dieting Exaggerates Liver Steatosis and Lesions but Preserves Muscle Performance in Male Zebrafish
    Tzu-Chieh Hsu, Chun-Hsien Chiang, I-Hsuan Liu, Chih-Yun Wang, Ching-Yi Chen
    International Journal of Molecular Sciences.2024; 25(23): 13225.     CrossRef
  • Weight variability, physical functioning and incident disability in older adults
    Katie J. McMenamin, Tamara B. Harris, Joshua F. Baker
    Journal of Cachexia, Sarcopenia and Muscle.2023; 14(4): 1648.     CrossRef
  • Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway
    Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
    Endocrinology and Metabolism.2022; 37(1): 74.     CrossRef
  • Triglyceride and glucose index is a simple and easy‐to‐calculate marker associated with nonalcoholic fatty liver disease
    Kyung‐Soo Kim, Sangmo Hong, Hong‐Yup Ahn, Cheol‐Young Park
    Obesity.2022; 30(6): 1279.     CrossRef
  • Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight
    Mohammed Eslam, Hashem B. El-Serag, Sven Francque, Shiv K. Sarin, Lai Wei, Elisabetta Bugianesi, Jacob George
    Nature Reviews Gastroenterology & Hepatology.2022; 19(10): 638.     CrossRef
  • Impact of COVID-19 Lockdown on Non-Alcoholic Fatty Liver Disease and Insulin Resistance in Adults: A before and after Pandemic Lockdown Longitudinal Study
    Ángel Arturo López-González, Bárbara Altisench Jané, Luis Masmiquel Comas, Sebastiana Arroyo Bote, Hilda María González San Miguel, José Ignacio Ramírez Manent
    Nutrients.2022; 14(14): 2795.     CrossRef
  • Higher Weight Variability Could Bring You a Fatty Liver
    Yeoree Yang, Jae-Hyoung Cho
    Endocrinology and Metabolism.2021; 36(4): 766.     CrossRef
  • Autonomic Imbalance Increases the Risk for Non-alcoholic Fatty Liver Disease
    Inha Jung, Da Young Lee, Mi Yeon Lee, Hyemi Kwon, Eun-Jung Rhee, Cheol-Young Park, Ki-Won Oh, Won-Young Lee, Sung-Woo Park, Se Eun Park
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
Close layer
Diabetes, Obesity and Metabolism
Non-Laboratory-Based Simple Screening Model for Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Developed Using Multi-Center Cohorts
Jiwon Kim, Minyoung Lee, Soo Yeon Kim, Ji-Hye Kim, Ji Sun Nam, Sung Wan Chun, Se Eun Park, Kwang Joon Kim, Yong-ho Lee, Joo Young Nam, Eun Seok Kang
Endocrinol Metab. 2021;36(4):823-834.   Published online August 27, 2021
DOI: https://doi.org/10.3803/EnM.2021.1074
  • 6,418 View
  • 152 Download
  • 2 Web of Science
  • 2 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent cause of chronic liver disease worldwide. Type 2 diabetes mellitus (T2DM) is a risk factor that accelerates NAFLD progression, leading to fibrosis and cirrhosis. Thus, here we aimed to develop a simple model to predict the presence of NAFLD based on clinical parameters of patients with T2DM.
Methods
A total of 698 patients with T2DM who visited five medical centers were included. NAFLD was evaluated using transient elastography. Univariate logistic regression analyses were performed to identify potential contributors to NAFLD, followed by multivariable logistic regression analyses to create the final prediction model for NAFLD.
Results
Two NAFLD prediction models were developed, with and without serum biomarker use. The non-laboratory model comprised six variables: age, sex, waist circumference, body mass index (BMI), dyslipidemia, and smoking status. For a cutoff value of ≥60, the prediction accuracy was 0.780 (95% confidence interval [CI], 0.743 to 0.817). The second comprehensive model showed an improved discrimination ability of up to 0.815 (95% CI, 0.782 to 0.847) and comprised seven variables: age, sex, waist circumference, BMI, glycated hemoglobin, triglyceride, and alanine aminotransferase to aspartate aminotransferase ratio. Our non-laboratory model showed non-inferiority in the prediction of NAFLD versus previously established models, including serum parameters.
Conclusion
The new models are simple and user-friendly screening methods that can identify individuals with T2DM who are at high-risk for NAFLD. Additional studies are warranted to validate these new models as useful predictive tools for NAFLD in clinical practice.

Citations

Citations to this article as recorded by  
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Non-Alcoholic Fatty Liver Disease or Type 2 Diabetes Mellitus—The Chicken or the Egg Dilemma
    Marcin Kosmalski, Agnieszka Śliwińska, Józef Drzewoski
    Biomedicines.2023; 11(4): 1097.     CrossRef
Close layer
Diabetes, Obesity and Metabolism
High Fibrosis-4 Index Is Related with Worse Clinical Outcome in Patients with Coronavirus Disease 2019 and Diabetes Mellitus: A Multicenter Observational Study
Sung-Woo Kim, Jae-Han Jeon, Jun Sung Moon, Mi Kyung Kim
Endocrinol Metab. 2021;36(4):800-809.   Published online August 20, 2021
DOI: https://doi.org/10.3803/EnM.2021.1040
  • 7,009 View
  • 186 Download
  • 10 Web of Science
  • 7 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
Based on recent evidence on the importance of the presence of diabetes mellitus (DM) and fibrosis-4 (FIB-4) index in coronavirus disease 2019 (COVID-19) mortality, we analyzed whether these factors could additively predict such mortality.
Methods
This multicenter observational study included 1,019 adult inpatients admitted to university hospitals in Daegu. The demographic and laboratory findings, mortality, prevalence of severe disease, and duration of quarantine were compared between patients with and without DM and/or a high FIB-4 index. The mortality risk and corresponding hazard ratio (HR) were analyzed using the Kaplan-Meier method and Cox proportional hazard models.
Results
The patients with DM (n=217) exhibited significantly higher FIB-4 index and mortality compared to those without DM. Although DM (HR, 2.66; 95% confidence interval [CI], 1.63 to 4.33) and a high FIB-4 index (HR, 4.20; 95% CI, 2.21 to 7.99) were separately identified as risk factors for COVID-19 mortality, the patients with both DM and high FIB-4 index had a significantly higher mortality (HR, 9.54; 95% CI, 4.11 to 22.15). Higher FIB-4 indices were associated with higher mortality regardless of DM. A high FIB-4 index with DM was more significantly associated with a severe clinical course with mortality (odds ratio, 11.24; 95% CI, 5.90 to 21.41) than a low FIB-4 index without DM, followed by a high FIB-4 index alone and DM alone. The duration of quarantine and hospital stay also tended to be longer in those with both DM and high FIB-4 index.
Conclusion
Both DM and high FIB-4 index are independent and additive risk factors for COVID-19 mortality.

Citations

Citations to this article as recorded by  
  • The clinical features and outcomes of diabetes patients infected with COVID-19: a systematic review and meta-analysis comprising 192,693 patients
    Kai Liu, Shu Liu, Ting-ting Xu, Hong Qiao
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Impact of liver fibrosis on COVID-19 in-hospital mortality in Southern Italy
    Raffaele Galiero, Giuseppe Loffredo, Vittorio Simeon, Alfredo Caturano, Erica Vetrano, Giulia Medicamento, Maria Alfano, Domenico Beccia, Chiara Brin, Sara Colantuoni, Jessica Di Salvo, Raffaella Epifani, Riccardo Nevola, Raffaele Marfella, Celestino Sard
    PLOS ONE.2024; 19(5): e0296495.     CrossRef
  • COVID-19 and hepatic injury: Diversity and risk assessment
    Fares E M Ali, Mostafa K Abd El-Aziz, Mahmoud M Ali, Osama M Ghogar, Adel G Bakr
    World Journal of Gastroenterology.2023; 29(3): 425.     CrossRef
  • Differential Effects of COVID-19 Hospitalization on the Trajectory of Liver Disease Progression
    Dilara Hatipoğlu, Connor Mulligan, Jeffrey Wang, Juan Peticco, Reid Grinspoon, Sanjay Gadi, Camilla Mills, Jay Luther, Raymond T. Chung
    Gastro Hep Advances.2023; 2(4): 480.     CrossRef
  • Association of non-alcoholic fatty liver and metabolic-associated fatty liver with COVID-19 outcomes: A systematic review and meta-analysis
    Gowthami Sai Kogilathota Jagirdhar, Rakhtan K Qasba, Harsha Pattnaik, Kaanthi Rama, Akshat Banga, Shiva Teja Reddy, Anna Carolina Flumignan Bucharles, Rahul Kashyap, Praveen Reddy Elmati, Vikas Bansal, Yatinder Bains, Theodore DaCosta, Salim Surani
    World Journal of Gastroenterology.2023; 29(21): 3362.     CrossRef
  • COVID-19 and Fatty Liver Disorders
    Maria Guarino, Valentina Cossiga, Francesco Cutolo, Maria Attanasio, Raffaele Lieto, Filomena Morisco
    Journal of Clinical Medicine.2023; 12(13): 4316.     CrossRef
  • Prevalence and Prognostic Significance of Liver Fibrosis in Patients With Aneurysmal Subarachnoid Hemorrhage
    Tiangui Li, Peng Wang, Xiao Gong, Weelic Chong, Yang Hai, Chao You, Juan Kang, Fang Fang, Yu Zhang
    Frontiers in Neurology.2022;[Epub]     CrossRef
Close layer
Clinical Study
Development of a Non-Invasive Liver Fibrosis Score Based on Transient Elastography for Risk Stratification in Patients with Type 2 Diabetes
Chi-Ho Lee, Wai-Kay Seto, Kelly Ieong, David T.W. Lui, Carol H.Y. Fong, Helen Y. Wan, Wing-Sun Chow, Yu-Cho Woo, Man-Fung Yuen, Karen S.L. Lam
Endocrinol Metab. 2021;36(1):134-145.   Published online February 24, 2021
DOI: https://doi.org/10.3803/EnM.2020.887
  • 6,282 View
  • 150 Download
  • 8 Web of Science
  • 9 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
In non-alcoholic fatty liver disease (NAFLD), transient elastography (TE) is an accurate non-invasive method to identify patients at risk of advanced fibrosis (AF). We developed a diabetes-specific, non-invasive liver fibrosis score based on TE to facilitate AF risk stratification, especially for use in diabetes clinics where TE is not readily available.
Methods
Seven hundred sixty-six adults with type 2 diabetes and NAFLD were recruited and randomly divided into a training set (n=534) for the development of diabetes fibrosis score (DFS), and a testing set (n=232) for internal validation. DFS identified patients with AF on TE, defined as liver stiffness (LS) ≥9.6 kPa, based on a clinical model comprising significant determinants of LS with the lowest Akaike information criteria. The performance of DFS was compared with conventional liver fibrosis scores (NFS, FIB-4, and APRI), using area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, positive and negative predictive values (NPV).
Results
DFS comprised body mass index, platelet, aspartate aminotransferase, high-density lipoprotein cholesterol, and albuminuria, five routine measurements in standard diabetes care. Derived low and high DFS cut-offs were 0.1 and 0.3, with 90% sensitivity and 90% specificity, respectively. Both cut-offs provided better NPVs of >90% than conventional fibrosis scores. The AUROC of DFS for AF on TE was also higher (P<0.01) than the conventional fibrosis scores, being 0.85 and 0.81 in the training and testing sets, respectively.
Conclusion
Compared to conventional fibrosis scores, DFS, with a high NPV, more accurately identified diabetes patients at-risk of AF, who need further evaluation by hepatologists.

Citations

Citations to this article as recorded by  
  • Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes—A real‐world study
    Chi‐Ho Lee, David Tak‐Wai Lui, Lung‐Yi Mak, Carol Ho‐Yi Fong, Kylie Sze‐Wing Chan, Jimmy Ho‐Cheung Mak, Chloe Yu‐Yan Cheung, Wing‐Sun Chow, Yu‐Cho Woo, Man‐Fung Yuen, Wai‐Kay Seto, Karen Siu‐Ling Lam
    Diabetes, Obesity and Metabolism.2025; 27(2): 574.     CrossRef
  • MOVING DIAGNOSIS OF LIVER FIBROSIS INTO THE COMMUNITY
    Elisa Pose, Salvatore Piano, Maja Thiele, Núria Fabrellas, Emmanuel A. Tsochatzis, Pere Ginès
    Journal of Hepatology.2025;[Epub]     CrossRef
  • Implementation of a liver health check in people with type 2 diabetes
    Kushala W M Abeysekera, Luca Valenti, Zobair Younossi, John F Dillon, Alina M Allen, Mazen Noureddin, Mary E Rinella, Frank Tacke, Sven Francque, Pere Ginès, Maja Thiele, Philip N Newsome, Indra Neil Guha, Mohammed Eslam, Jörn M Schattenberg, Saleh A Alqa
    The Lancet Gastroenterology & Hepatology.2024; 9(1): 83.     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Sequential algorithm to stratify liver fibrosis risk in overweight/obese metabolic dysfunction-associated fatty liver disease
    Chi-Ho Lee, David Tak-Wai Lui, Raymond Hang-Wun Li, Michele Mae-Ann Yuen, Carol Ho-Yi Fong, Ambrose Pak-Wah Leung, Justin Chiu-Man Chu, Loey Lung-Yi Mak, Tai-Hing Lam, Jean Woo, Yu-Cho Woo, Aimin Xu, Hung-Fat Tse, Kathryn Choon-Beng Tan, Bernard Man-Yung
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Non-Invasive Measurement of Hepatic Fibrosis by Transient Elastography: A Narrative Review
    Luca Rinaldi, Chiara Giorgione, Andrea Mormone, Francesca Esposito, Michele Rinaldi, Massimiliano Berretta, Raffaele Marfella, Ciro Romano
    Viruses.2023; 15(8): 1730.     CrossRef
  • Metabolic dysfunction-associated fatty liver disease — How relevant is this to primary care physicians and diabetologists?
    Chi-Ho Lee
    Primary Care Diabetes.2022; 16(2): 245.     CrossRef
  • Non‐alcoholic fatty liver disease and type 2 diabetes: An update
    Chi‐H Lee, David TW Lui, Karen SL Lam
    Journal of Diabetes Investigation.2022; 13(6): 930.     CrossRef
  • Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes
    Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai
    Biomedicines.2022; 10(10): 2375.     CrossRef
Close layer
Review Article
Obesity and Metabolism
Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease
Dae Ho Lee
Endocrinol Metab. 2020;35(2):243-259.   Published online June 24, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.2.243
  • 14,062 View
  • 332 Download
  • 22 Web of Science
  • 24 Crossref
AbstractAbstract PDFPubReader   ePub   
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver diseases and can progress to advanced fibrosis and end-stage liver disease. Thus, intensive research has been performed to develop noninvasive methods for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. Currently, no single noninvasive tool covers all of the stages of pathologies and conditions of NAFLD, and the cost and feasibility of known techniques are also important issues. Blood biomarkers for NAFLD may be useful to select subjects who need ultrasonography (US) screening for NAFLD, and noninvasive tools for assessing fibrosis may be helpful to exclude the probability of significant fibrosis and to predict advanced fibrosis, thus guiding the decision of whether to perform liver biopsy in patients with NAFLD. Among various methods, magnetic resonance-based methods have been shown to perform better than other methods in assessing steatosis as well as in detecting hepatic fibrosis. Many genetic markers are associated with the development and progression of NAFLD. Further well-designed studies are needed to determine which biomarker panels, imaging studies, genetic marker panels, or combinations thereof perform well for diagnosing NAFLD, differentiating NASH and fibrosis, and following-up NAFLD, respectively.

Citations

Citations to this article as recorded by  
  • Recent Progresses on Pathophysiology, Diagnosis, Therapeutic Modalities, and Management of Non-alcoholic Fatty Liver Disorder
    Mahdi Barazesh, Sajad Jalili, Morteza Akhzari, Fouzieyeh Faraji, Ebrahim Khorramdin
    Current Drug Therapy.2024; 19(1): 20.     CrossRef
  • Intact ketogenesis predicted reduced risk of moderate-severe metabolic-associated fatty liver disease assessed by liver transient elastography in newly diagnosed type 2 diabetes
    Sejeong Lee, Jaehyun Bae, Seung Up Kim, Minyoung Lee, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Association between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction: A 7-year retrospective cohort study of 3,380 adults using serial echocardiography
    Gyuri Kim, Tae Yang Yu, Jae Hwan Jee, Ji Cheol Bae, Mira Kang, Jae Hyeon Kim
    Diabetes & Metabolism.2024; 50(3): 101534.     CrossRef
  • Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Monica A. Tincopa, Rohit Loomba
    Seminars in Liver Disease.2024; 44(03): 287.     CrossRef
  • A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease
    Seung Joon Choi, Sungjin Yoon, Kyoung-Kon Kim, Doojin Kim, Hye Eun Lee, Kwang Gi Kim, Seung Kak Shin, Ie Byung Park, Seong Min Kim, Dae Ho Lee
    Diabetes & Metabolism Journal.2024; 48(4): 740.     CrossRef
  • Evaluating the role of IER3+ macrophages in the prognosis of liver fibrosis by bulk and single-cell transcriptional analyses
    Ling Chu, Junbo Zhang, Ruoyu Meng, Quan Zhuang
    iLIVER.2024; 3(4): 100132.     CrossRef
  • Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
    Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
    Diabetes & Metabolism Journal.2023; 47(2): 220.     CrossRef
  • Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Monica A Tincopa, Rohit Loomba
    The Lancet Gastroenterology & Hepatology.2023; 8(7): 660.     CrossRef
  • Hepatic Involvement across the Metabolic Syndrome Spectrum: Non-Invasive Assessment and Risk Prediction Using Machine Learning
    Adelaida Solomon, Călin Remus Cipăian, Mihai Octavian Negrea, Adrian Boicean, Romeo Mihaila, Corina Beca, Mirela Livia Popa, Sebastian Mihai Grama, Minodora Teodoru, Bogdan Neamtu
    Journal of Clinical Medicine.2023; 12(17): 5657.     CrossRef
  • Greater Severity of Steatosis Is Associated with a Higher Risk of Incident Diabetes: A Retrospective Longitudinal Study
    Ji Min Han, Jung Hwan Cho, Hye In Kim, Sunghwan Suh, Yu-Ji Lee, Jung Won Lee, Kwang Min Kim, Ji Cheol Bae
    Endocrinology and Metabolism.2023; 38(4): 418.     CrossRef
  • Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease
    Georgiana-Emmanuela Gîlcă-Blanariu, Daniela Simona Budur, Dana Elena Mitrică, Elena Gologan, Oana Timofte, Gheorghe Gh Bălan, Vasile Andrei Olteanu, Gabriela Ștefănescu
    Metabolites.2023; 13(11): 1115.     CrossRef
  • Plasma Aldo-Keto Reductase Family 1 Member B10 as a Biomarker Performs Well in the Diagnosis of Nonalcoholic Steatohepatitis and Fibrosis
    Aron Park, Seung Joon Choi, Sungjin Park, Seong Min Kim, Hye Eun Lee, Minjae Joo, Kyoung Kon Kim, Doojin Kim, Dong Hae Chung, Jae Been Im, Jaehun Jung, Seung Kak Shin, Byung-Chul Oh, Cheolsoo Choi, Seungyoon Nam, Dae Ho Lee
    International Journal of Molecular Sciences.2022; 23(9): 5035.     CrossRef
  • Triglyceride and glucose index is a simple and easy‐to‐calculate marker associated with nonalcoholic fatty liver disease
    Kyung‐Soo Kim, Sangmo Hong, Hong‐Yup Ahn, Cheol‐Young Park
    Obesity.2022; 30(6): 1279.     CrossRef
  • The Impact of Insulin Resistance on Hepatic Fibrosis among United States Adults with Non-Alcoholic Fatty Liver Disease: NHANES 2017 to 2018
    Ji Cheol Bae, Lauren A. Beste, Kristina M. Utzschneider
    Endocrinology and Metabolism.2022; 37(3): 455.     CrossRef
  • Plasma Metabolomics and Machine Learning-Driven Novel Diagnostic Signature for Non-Alcoholic Steatohepatitis
    Moongi Ji, Yunju Jo, Seung Joon Choi, Seong Min Kim, Kyoung Kon Kim, Byung-Chul Oh, Dongryeol Ryu, Man-Jeong Paik, Dae Ho Lee
    Biomedicines.2022; 10(7): 1669.     CrossRef
  • Evaluation of Liver Changes in Type-2 Diabetes Mellitus Patients using Computed Tomography
    Nayyar Ashfaq, Akash John, Abid Ali, Amina Sharif Bhatti, Hateem Qaiser
    DIET FACTOR (Journal of Nutritional & Food Sciences).2022; : 14.     CrossRef
  • Accuracy of FIB-4 to Detect Elevated Liver Stiffness Measurements in Patients with Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study in Referral Centers
    Mauro Viganò, Nicola Pugliese, Federica Cerini, Federica Turati, Vincenzo Cimino, Sofia Ridolfo, Simone Rocchetto, Francesca Foglio, Maria Terrin, Carlo La Vecchia, Maria Grazia Rumi, Alessio Aghemo
    International Journal of Molecular Sciences.2022; 23(20): 12489.     CrossRef
  • MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy
    Ying-Xin Xian, Jian-Ping Weng, Fen Xu
    Chinese Medical Journal.2021; 134(1): 8.     CrossRef
  • Prognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: A systematic review
    Jenny Lee, Yasaman Vali, Jerome Boursier, Rene Spijker, Quentin M. Anstee, Patrick M. Bossuyt, Mohammad H. Zafarmand
    Liver International.2021; 41(2): 261.     CrossRef
  • Serum syndecan‐4 is associated with nonalcoholic fatty liver disease
    Shu Jing Xia, Li Zhong Tang, Wen Hua Li, Zhao Shan Xu, Li Li Zhang, Feng Gan Cheng, Hong Xia Chen, Zi Hua Wang, Yu Cheng Luo, An Na Dai, Jian Gao Fan
    Journal of Digestive Diseases.2021; 22(9): 536.     CrossRef
  • Non-Laboratory-Based Simple Screening Model for Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Developed Using Multi-Center Cohorts
    Jiwon Kim, Minyoung Lee, Soo Yeon Kim, Ji-Hye Kim, Ji Sun Nam, Sung Wan Chun, Se Eun Park, Kwang Joon Kim, Yong-ho Lee, Joo Young Nam, Eun Seok Kang
    Endocrinology and Metabolism.2021; 36(4): 823.     CrossRef
  • Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up
    Suguru Ikeda, Takaaki Sugihara, Takuya Kihara, Yukako Matsuki, Takakazu Nagahara, Tomoaki Takata, Sonoko Kitao, Tsuyoshi Okura, Kazuhiro Yamamoto, Hajime Isomoto
    Diagnostics.2021; 11(12): 2316.     CrossRef
  • Triglyceride Glucose-Waist Circumference Is Superior to the Homeostasis Model Assessment of Insulin Resistance in Identifying Nonalcoholic Fatty Liver Disease in Healthy Subjects
    Hwi Seung Kim, Yun Kyung Cho, Eun Hee Kim, Min Jung Lee, Chang Hee Jung, Joong-Yeol Park, Hong-Kyu Kim, Woo Je Lee
    Journal of Clinical Medicine.2021; 11(1): 41.     CrossRef
  • The Leg Fat to Total Fat Ratio Is Associated with Lower Risks of Non-Alcoholic Fatty Liver Disease and Less Severe Hepatic Fibrosis: Results from Nationwide Surveys (KNHANES 2008–2011)
    Hyun Min Kim, Yong-ho Lee
    Endocrinology and Metabolism.2021; 36(6): 1232.     CrossRef
Close layer
Original Article
Clinical Study
Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis
Chan-Hee Jung, Eun-Jung Rhee, Hyemi Kwon, Yoosoo Chang, Seungho Ryu, Won-Young Lee
Endocrinol Metab. 2020;35(1):165-176.   Published online March 19, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.1.165
  • 8,737 View
  • 153 Download
  • 36 Web of Science
  • 39 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

We evaluated the association of visceral-to-subcutaneous fat ratio (VSR) with nonalcoholic fatty liver disease (NAFLD) and advanced fibrosis degree based on noninvasive serum fibrosis markers in the general population with NAFLD.

Methods

This is a cross-sectional study, in 7,465 Korean adults who underwent health screening examinations. NAFLD was defined as fatty liver detected on ultrasonography, and visceral and subcutaneous abdominal fat was measured using computed tomography. We predicted fibrosis based on the fibrosis-4 (FIB-4) score and aspartate aminotransferase-to-platelet ratio index (APRI) and categorized the risk for advanced fibrosis as low, indeterminate, or high.

Results

The multivariable-adjusted prevalence ratios for indeterminate to high risk of advanced fibrosis based on FIB-4, determined by comparing the second, third, and fourth quartiles with the first quartile of VSR, were 3.38 (95% confidence interval [CI], 0.64 to 17.97), 9.41 (95% CI, 1.97 to 45.01), and 19.34 (95% CI, 4.06 to 92.18), respectively. The multivariable-adjusted prevalence ratios for intermediate to high degree of fibrosis according to APRI also increased across VSR quartiles (5.04 [95% CI, 2.65 to 9.59], 7.51 [95% CI, 3.91 to 14.42], and 19.55 [95% CI, 9.97 to 38.34], respectively). High VSR was more strongly associated with the prevalence of NAFLD in nonobese subjects than in obese subjects, and the associations between VSR and intermediate to high probability of advanced fibrosis in NAFLD were stronger in obese subjects than in nonobese subjects.

Conclusion

High VSR values predicted increased NAFLD risk and advanced fibrosis risk with NAFLD, and the predictive value of VSR for indeterminate to high risk of advanced fibrosis was higher in obese subjects than in nonobese subjects.

Citations

Citations to this article as recorded by  
  • Serial changes in metabolic dysfunction-associated steatotic liver disease after sleeve gastrectomy and their associations with abdominal adiposity: a prospective cohort study
    Chung-Yi Yang, Jian-Han Chen, Chung-Yen Chen, Cheng-Yi Kao, Shiu-Feng Huang, Wen-Yu Chang, Hung-Pin Tu, Jee-Fu Huang, Ming-Lung Yu, Chi-Ming Tai
    Surgery for Obesity and Related Diseases.2025; 21(5): 537.     CrossRef
  • The relationship between anthropometric indices and non-alcoholic fatty liver disease in adults: a cross-sectional study
    Mina Radmehr, Reza Homayounfar, Abolghasem Djazayery
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Nomogram for predicting severe abdominal adhesions prior to definitive surgery in patients with anastomotic fistula post-small intestine resection: a cohort study
    Zheng Yao, Weiwei Shang, Fan Yang, Weiliang Tian, Guoping Zhao, Xin Xu, Risheng Zhao MD, Tao Tian, Wuhan Li, Ming Huang, Yunzhao Zhao, Qian Huang
    International Journal of Surgery.2025; 111(2): 2046.     CrossRef
  • Opportunistic Extraction of Quantitative CT Biomarkers: Turning the Incidental Into Prognostic Information
    Mohammad Nazri Md Shah, Raja Rizal Azman, Wai Yee Chan, Kwan Hoong Ng
    Canadian Association of Radiologists Journal.2024; 75(1): 92.     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Association between obesity phenotypes and non-alcoholic fatty liver: a large population- based study
    Farid Najafi, Yahya Pasdar, Mehdi Moradi Nazar, Mitra Darbandi
    BMC Endocrine Disorders.2024;[Epub]     CrossRef
  • Regional fat distribution and hepatic fibrosis and steatosis severity in patients with nonalcoholic fatty liver disease and type 2 diabetes
    Asieh Mansour, Saeed Pourhassan, Hadis Gerami, Mohammad Reza Mohajeri‐Tehrani, Marziye Salahshour, Ali Abbasi, Elham Madreseh, Sayed Mahmoud Sajjadi‐Jazi
    Obesity Science & Practice.2024;[Epub]     CrossRef
  • Visceral to subcutaneous fat area ratio predicts severe abdominal adhesions in definitive surgery for anastomotic fistula after small intestine resection
    Fan Yang, Weiliang Tian, Shikun Luo, Wuhan Li, Guoping Zhao, Risheng Zhao, Tao Tian, Yunzhao Zhao, Zheng Yao, Qian Huang
    Scientific Reports.2024;[Epub]     CrossRef
  • Obesity. Reasons, features and prospects
    E. A. Bondareva, E. A. Troshina
    Obesity and metabolism.2024; 21(2): 174.     CrossRef
  • Differential association of abdominal, liver, and epicardial adiposity with anthropometry, diabetes, and cardiac remodeling in Asians
    Vivian Lee, Yiying Han, Desiree-Faye Toh, Jennifer A. Bryant, Redha Boubertakh, Thu-Thao Le, Calvin W. L. Chin
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Serum immunoglobulin A levels: Diagnostic utility in alcoholic liver disease and association with liver fibrosis in steatotic liver disease
    Tatsuki Ichikawa, Mio Yamashima, Shinobu Yamamichi, Makiko Koike, Yusuke Nakano, Hiroyuki Yajima, Osamu Miyazaki, Tomonari Ikeda, Takuma Okamura, Kazuyoshi Nagata, Kenichi Sawa, Kazutaka Niiya, Kazuhiko Nakao
    Biomedical Reports.2024;[Epub]     CrossRef
  • Helicobacter pylori Infection Is Not Associated with Nonalcoholic Fatty Liver Disease: A Two-Year Cohort Study
    Huabo Zheng, Tangmeng Guo, Xiaofang Zhao, Kun Wang, Shengshuai Shan, Songpu Xie, Yichen Xu, Chengyun Liu, Weilin Lu
    Digestive Diseases.2024; : 1.     CrossRef
  • Association between Knowledge and Practice of Thermally Abused Cooking Oil, Serum Lipid Profile, Body Composition, and Waist Circumference of Hyperlipidemia Patients Running Title: Usage of Reused Cooking Oil on Health Parameters
    Siow Lean Yi, Divya Vanoh
    Malaysian Journal of Medicine and Health Sciences.2024; 20(4): 79.     CrossRef
  • Positive Association Between the Chinese Visceral Adiposity Index and Nonalcoholic Fatty Liver Disease in Lean Adults
    Shuxia Shen, Hangkai Huang, Jinghua Wang, Zexi Tang, Chao Shen, Chengfu Xu
    Digestive Diseases and Sciences.2023; 68(2): 656.     CrossRef
  • Association between Sarcopenic Obesity Status and Nonalcoholic Fatty Liver Disease and Fibrosis
    Wolhwa Song, Sung Hwan Yoo, Jinsun Jang, Su Jung Baik, Byoung Kwon Lee, Hyun Woong Lee, Jong Suk Park
    Gut and Liver.2023; 17(1): 130.     CrossRef
  • Using hyperhomocysteinemia and body composition to predict the risk of non-alcoholic fatty liver disease in healthcare workers
    Xiaoyan Hao, Honghai He, Liyuan Tao, Peng Wang
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Visceral and subcutaneous fat, muscle mass, and liver volume as noninvasive predictors of the progress of non-alcoholic fatty liver disease
    Omar M. Mahmoud, Gehad Abd Elaziz Mahmoud, Haisam Atta, Wael A. Abbas, Hanan M. Ahmed, Mohamed A. A. Abozaid
    Egyptian Journal of Radiology and Nuclear Medicine.2023;[Epub]     CrossRef
  • Relationship between metabolic associated fatty liver disease and body fat ratio, visceral fat area, and resting metabolic rate estimated by bioelectrical impedance analysis
    Deng-Hua He, Yong-Zhan Zhang, Liang Xu, Jia-Jia Pei, Ying Zhang, Zhong-Fang Yan
    World Chinese Journal of Digestology.2023; 31(2): 56.     CrossRef
  • Poor glycaemic control and ectopic fat deposition mediates the increased risk of non-alcoholic steatohepatitis in high-risk populations with type 2 diabetes: Insights from Bayesian-network modelling
    T. Waddell, A. Namburete, P. Duckworth, A. Fichera, A. Telford, H. Thomaides-Brears, D. J. Cuthbertson, M. Brady
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
    Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
    Diabetes & Metabolism Journal.2023; 47(2): 220.     CrossRef
  • Subcutaneous Fat Obesity in a High Body Mass Index Donor Is Not a Contraindication to Living Donor Hepatectomy
    Hirak Pahari, Amey Sonavane, Amruth Raj, Anup Kumar Agrawal, Ambreen Sawant, Deepak Kumar Gupta, Amit Gharat, Vikram Raut, Sorabh Kapoor
    Case Reports in Hepatology.2023; 2023: 1.     CrossRef
  • Comparison of cardiometabolic risk factors between obese and non-obese patients with nonalcoholic fatty liver disease
    Zahra Yari, Danial Fotros, Azita Hekmatdoost
    Scientific Reports.2023;[Epub]     CrossRef
  • Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity
    Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe
    Clinical and Molecular Hepatology.2023; 29(4): 987.     CrossRef
  • Visceral Adipose Tissue Inflammation and Radiographic Visceral-to-Subcutaneous Adipose Tissue Ratio in Patients with Cirrhosis
    Nghiem B. Ha, Soo-Jin Cho, Yara Mohamad, Dorothea Kent, Grace Jun, Randi Wong, Vivek Swarnakar, Shezhang Lin, Jacquelyn J. Maher, Jennifer C. Lai
    Digestive Diseases and Sciences.2022; 67(7): 3436.     CrossRef
  • The Influence of Obesity and Metabolic Health on Vascular Health
    Eun-Jung Rhee
    Endocrinology and Metabolism.2022; 37(1): 1.     CrossRef
  • The effect of combined exercises on the plasma levels of retinol-binding protein 4 and its relationship with insulin resistance and hepatic fat content in postmenopausal women with nonalcoholic fatty liver disease
    Masoumeh NOROUZPOUR, Sayyed M. MARANDI, Mohsen GHANBARZADEH, Abbasali ZARE MAIVAN
    The Journal of Sports Medicine and Physical Fitness.2022;[Epub]     CrossRef
  • The Perirenal Fat Thickness Was Associated with Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus
    Yuxian Yang, Shuting Li, Yuechao Xu, Jing Ke, Dong Zhao
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 1505.     CrossRef
  • Visceral adiposity is an independent risk factor for high intra-operative blood loss during living-donor liver transplantation; could preoperative rehabilitation and nutritional therapy mitigate that risk?
    Mahmoud Macshut, Toshimi Kaido, Siyuan Yao, Yosuke Miyachi, Mohamed Sharshar, Sena Iwamura, Masaaki Hirata, Hisaya Shirai, Naoko Kamo, Shintaro Yagi, Shinji Uemoto
    Clinical Nutrition.2021; 40(3): 956.     CrossRef
  • A review of non‐alcoholic fatty liver disease in non‐obese and lean individuals
    Mitra Ahadi, Kasra Molooghi, Negin Masoudifar, Ali Beheshti Namdar, Hassan Vossoughinia, Mohammadreza Farzanehfar
    Journal of Gastroenterology and Hepatology.2021; 36(6): 1497.     CrossRef
  • Quantification of abdominal fat from computed tomography using deep learning and its association with electronic health records in an academic biobank
    Matthew T MacLean, Qasim Jehangir, Marijana Vujkovic, Yi-An Ko, Harold Litt, Arijitt Borthakur, Hersh Sagreiya, Mark Rosen, David A Mankoff, Mitchell D Schnall, Haochang Shou, Julio Chirinos, Scott M Damrauer, Drew A Torigian, Rotonya Carr, Daniel J Rader
    Journal of the American Medical Informatics Association.2021; 28(6): 1178.     CrossRef
  • Hepatic Steatosis in Patients With Single Ventricle and a Fontan Circulation
    David A. Katz, Daniel Peck, Adam M. Lubert, Mathias Possner, Faizeen Zafar, Andrew T. Trout, Joseph J. Palermo, Nadeem Anwar, Jonathan R. Dillman, Adam W. Powell, Stavra A. Xanthakos, Alexander R. Opotowsky, Gruschen Veldtman, Tarek Alsaied
    Journal of the American Heart Association.2021;[Epub]     CrossRef
  • Superficial vs Deep Subcutaneous Adipose Tissue: Sex-Specific Associations With Hepatic Steatosis and Metabolic Traits
    Tessa Brand, Inge Christina Lamberta van den Munckhof, Marinette van der Graaf, Kiki Schraa, Helena Maria Dekker, Leonardus Antonius Bernardus Joosten, Mihai Gheorghe Netea, Niels Peter Riksen, Jacqueline de Graaf, Joseph Henricus Wilhelmus Rutten
    The Journal of Clinical Endocrinology & Metabolism.2021; 106(10): e3881.     CrossRef
  • Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: A cohort study
    Dae-Jeong Koo, Mi Yeon Lee, Inha Jung, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee, Ming-Lung Yu
    PLOS ONE.2021; 16(8): e0255535.     CrossRef
  • Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
    Anne Flint, Grit Andersen, Paul Hockings, Lars Johansson, Anni Morsing, Mads Sundby Palle, Thomas Vogl, Rohit Loomba, Leona Plum‐Mörschel
    Alimentary Pharmacology & Therapeutics.2021; 54(9): 1150.     CrossRef
  • Effects of IL-33 on 3T3-L1 cells and obese mice models induced by a high-fat diet
    Yue Kai, Jingtao Gao, Hu Liu, Yubing Wang, Chenrui Tian, Sheng Guo, Ling He, Min Li, Zhongwei Tian, Xiangfeng Song
    International Immunopharmacology.2021; 101: 108209.     CrossRef
  • Lipid Accumulation Product as an Index for Visceral Obesity and Cardiovascular Risk among a Sample of Obese Egyptian Women
    Nayera E. Hassan, Sahar A. El-Masry, Gamila S. M. El-Saeed, Mohamed S. El Hussieny
    Open Access Macedonian Journal of Medical Sciences.2021; 9(B): 1229.     CrossRef
  • Combined Effects of Dyslipidemia and High Adiposity on the Estimated Glomerular Filtration Rate in a Middle-Aged Chinese Population
    Xichang Wang, Haoyu Wang, Jiashu Li, Xiaotong Gao, Yutong Han, Weiping Teng, Zhongyan Shan, Yaxin Lai
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 4513.     CrossRef
  • Determination of “indeterminate score” measurements in lean nonalcoholic fatty liver disease patients from western Saudi Arabia
    Yasir Mohammed Khayyat
    World Journal of Hepatology.2021; 13(12): 2150.     CrossRef
  • Utility of Liver Function Tests and Fatty Liver Index to Categorize Metabolic Phenotypes in a Mediterranean Population
    Dariusz Narankiewicz, Josefina Ruiz-Nava, Veronica Buonaiuto, María Isabel Ruiz-Moreno, María Dolores López-Carmona, Luis Miguel Pérez-Belmonte, Ricardo Gómez-Huelgas, María Rosa Bernal-López
    International Journal of Environmental Research and Public Health.2020; 17(10): 3518.     CrossRef
Close layer
Namgok Lecture 2019
Obesity and Metabolism
Impact of Skeletal Muscle Mass on Metabolic Health
Gyuri Kim, Jae Hyeon Kim
Endocrinol Metab. 2020;35(1):1-6.   Published online March 19, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.1.1
  • 17,702 View
  • 412 Download
  • 84 Web of Science
  • 89 Crossref
AbstractAbstract PDFPubReader   ePub   

Skeletal muscle is regarded as an endocrine and paracrine organ. Muscle-derived secretory proteins, referred to as myokines, mediate interactions between skeletal muscle mass and other organs such as the liver, adipose tissue, pancreas, bone, and the cardiovascular system. As individuals age, reduced levels of physical activity and sarcopenia (loss of skeletal muscle mass and strength) are associated with physical frailty and disability. Recently, several studies have suggested that the loss of skeletal muscle mass may contribute to metabolic disease. Therefore, herein, we focus on the relationships between skeletal muscle mass and metabolic diseases, including metabolic syndrome and non-alcoholic fatty liver disease.

Citations

Citations to this article as recorded by  
  • Dietary Calcium-to-Phosphorous Ratio, Metabolic Risk Factors and Lipid Accumulation Product, Skeletal Muscle Mass, and Visceral Fat Area Among Healthy Young Individuals
    Xuanshang Jin, Xiangchuan Jin, Wen Guan, Maolin Tang
    International Journal of Sport Nutrition and Exercise Metabolism.2025; 35(1): 43.     CrossRef
  • Risk factors for metabolic syndrome are associated with low handgrip strength in people with HIV
    Izabella Bernardes Araujo, Camila Ferreira Silva, Eduardo Vignoto Fernandes, Morganna Alves Siqueira, Marília Brasil Xavier, Luiz Fernando Gouvêa-e-Silva
    Sport Sciences for Health.2025; 21(1): 465.     CrossRef
  • Changes in muscle performance among older adults with myeloid malignancies engaging in a mobile health (mHealth) exercise intervention: a single arm pilot study
    Marielle Jensen-Battaglia, Po-Ju Lin, Chandrika Sanapala, Erin E. Watson, Jason H. Mendler, Jane Liesveld, Ying Wang, Elisabeth Hayward, Marissa LoCastro, Soroush Mortaz, Richard F. Dunne, Karen Mustian, Kah Poh Loh
    BMC Geriatrics.2025;[Epub]     CrossRef
  • The Use of SGLT-2 Inhibitors and GLP-1RA in Frail Older People with Diabetes: A Personalised Approach Is Required
    Alan J. Sinclair, Ahmed H. Abdelhafiz
    Metabolites.2025; 15(1): 49.     CrossRef
  • Effects of 12-month physical and cognitive training on sarcopenia determinants in older adults: a subgroup analysis of a randomised clinical trial
    Onni Oskari Hämäläinen, Tiina Marketta Savikangas, Anna-Katriina Tirkkonen, Markku Juhani Alén, Arto Jorma Hautala, Sarianna Sipilä
    Aging Clinical and Experimental Research.2025;[Epub]     CrossRef
  • Preliminary Evidence Suggests That a 12-Week Treatment with Tirzepatide Plus Low-Energy Ketogenic Therapy Is More Effective than Its Combination with a Low-Calorie Diet in Preserving Fat-Free Mass, Muscle Strength, and Resting Metabolic Rate in Patients w
    Luigi Schiavo, Biagio Santella, Monica Mingo, Gianluca Rossetti, Marcello Orio, Luigi Cobellis, Attilio Maurano, Antonio Iannelli, Vincenzo Pilone
    Nutrients.2025; 17(7): 1216.     CrossRef
  • Effects of protein supplementation on muscle mass, muscle strength, and physical performance in older adults with physical inactivity: a systematic review and meta-analysis
    Liying Zhang, Gongxiang Liu, Xiaoli Huang, Fuqian He
    BMC Geriatrics.2025;[Epub]     CrossRef
  • Growth hormone–deficient Ames dwarf mice resist sarcopenia and exhibit enhanced endurance running performance at 24 months
    Matthew J. Johnston, Sharlene G. Rakoczy, LaDora V. Thompson, Holly M. Brown-Borg
    GeroScience.2025;[Epub]     CrossRef
  • Effects of a Combination of Morus bombycis Koidz. and Angelica keiskei Extracts on Muscle Atrophy in an Aging Mouse Model
    Hyun Hwangbo, Min Yeong Kim, Seon Yeong Ji, Da Hye Kim, Jae Hyun Yoon, Seong Un Jeong, Tae Hee Kim, Yung Hyun Choi
    Journal of the Korean Society of Food Science and Nutrition.2025; 54(3): 218.     CrossRef
  • Sex differences in the association between dual‐energy x‐ray absorptiometry‐measured body composition and periodontitis
    Peijun Zhu, An Li, Qingqing Cai, Yuntao Chen, Yang Liu, Harriët Jager‐Wittenaar, Geerten‐Has E. Tjakkes, Shulan Xu
    Journal of Periodontology.2024; 95(3): 219.     CrossRef
  • Advances in the treatment of functional male hypogonadism
    Giovanni Corona, Giulia Rastrelli, Clotilde Sparano, Linda Vignozzi, Alessandra Sforza, Mario Maggi
    Expert Review of Endocrinology & Metabolism.2024; 19(2): 163.     CrossRef
  • Heterogeneously elevated branched-chain/aromatic amino acids among new-onset type-2 diabetes mellitus patients are potentially skewed diabetes predictors
    Min Wang, Yang Ou, Xiang-Lian Yuan, Xiu-Fang Zhu, Ben Niu, Zhuang Kang, Bing Zhang, Anwar Ahmed, Guo-Qiang Xing, Heng Su
    World Journal of Diabetes.2024; 15(1): 53.     CrossRef
  • The Vicious Cycle of Type 2 Diabetes Mellitus and Skeletal Muscle Atrophy: Clinical, Biochemical, and Nutritional Bases
    Jose M. Lopez-Pedrosa, Maria Camprubi-Robles, German Guzman-Rolo, Andres Lopez-Gonzalez, Jose Manuel Garcia-Almeida, Alejandro Sanz-Paris, Ricardo Rueda
    Nutrients.2024; 16(1): 172.     CrossRef
  • FGF21 Induces Skeletal Muscle Atrophy and Increases Amino Acids in Female Mice: A Potential Role for Glucocorticoids
    Karlton R Larson, Devi Jayakrishnan, Karla A Soto Sauza, Michael L Goodson, Aki T Chaffin, Arik Davidyan, Suraj Pathak, Yanbin Fang, Diego Gonzalez Magaña, Benjamin F Miller, Karen K Ryan
    Endocrinology.2024;[Epub]     CrossRef
  • Sarcopenic Obesity and Cardiovascular Disease: An Overlooked but High-Risk Syndrome
    Saeid Mirzai, Salvatore Carbone, John A. Batsis, Stephen B. Kritchevsky, Dalane W. Kitzman, Michael D. Shapiro
    Current Obesity Reports.2024; 13(3): 532.     CrossRef
  • Mortality risk relationship using standard categorized BMI or knee-height based BMI – does the overweight/lower mortality paradox hold true?
    Nivetha Natarajan Gavriilidou, Mats Pihlsgård, Sölve Elmståhl, Henrik Ekström
    Aging Clinical and Experimental Research.2024;[Epub]     CrossRef
  • Gromwell (Lithospermum erythrorhizon) Attenuates High-Fat-Induced Skeletal Muscle Wasting by Increasing Protein Synthesis and Mitochondrial Biogenesis
    Ji-Sun Kim, Hyunjung Lee, Ahyoung Yoo, Hang Yeon Jeong, Chang Hwa Jung, Jiyun Ahn, Tae-Youl Ha
    Journal of Microbiology and Biotechnology.2024; 34(3): 495.     CrossRef
  • L-shaped association between lean body mass to visceral fat mass ratio with hyperuricemia: a cross-sectional study
    Longti Li, Ya Shao, Huiqin Zhong, Yu Wang, Rong Zhang, Boxiong Gong, Xiaoxv Yin
    Lipids in Health and Disease.2024;[Epub]     CrossRef
  • Effect of COVID‐19 pandemic on bioimpedance health indicators in young adults
    Darina Falbová, Radoslav Beňuš, Simona Sulis, Lenka Vorobeľová
    American Journal of Human Biology.2024;[Epub]     CrossRef
  • Sex difference in skeletal muscle mass in relation to metabolic dysfunction-associated steatotic liver disease: a propensity score matching study
    Da-Hye Son, Yu-Jin Kwon, Jun-Hyuk Lee
    The Journal of nutrition, health and aging.2024; 28(6): 100270.     CrossRef
  • Critical variables regulating age-related anabolic responses to protein nutrition in skeletal muscle
    Colleen S. Deane, Jake Cox, Philip J. Atherton
    Frontiers in Nutrition.2024;[Epub]     CrossRef
  • Molecular mechanism of skeletal muscle loss and its prevention by natural resources
    Jin Tae Kim, Dong Hyeon Jeon, Hong Jin Lee
    Food Science and Biotechnology.2024; 33(15): 3387.     CrossRef
  • Why you should not skip tailored exercise interventions when using incretin mimetics for weight loss
    Katharina Gross, Christian Brinkmann
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • The Effects of Blood Flow Restriction Aerobic Exercise on Body Composition, Muscle Strength, Blood Biomarkers, and Cardiovascular Function: A Narrative Review
    Chaeeun Cho, Sewon Lee
    International Journal of Molecular Sciences.2024; 25(17): 9274.     CrossRef
  • Low muscle mass is associated with efficacy of biologics in Crohn's disease
    Ye Fang, Luyan Fang, Mengqian Ye, Hanyue Jiang, Xinyu Long, Haoxuan Zhang, Qianqian Zhang, Daopo Lin, Xiaoxiao Shao
    Clinical Nutrition.2024; 43(10): 2354.     CrossRef
  • Pre-Transplant Dual-Energy X-ray Absorptiometry (DXA)-Derived Body Composition Measures as Predictors of Treatment Outcomes and Early Post-Transplant Complications in Patients with Multiple Myeloma (MM) Treated with Autologous Hematopoietic Stem Cell Tran
    Paula Jabłonowska-Babij, Diana Jędrzejuk, Maciej Majcherek, Agnieszka Szeremet, Magdalena Karasek, Bartłomiej Kuszczak, Krzysztof Kujawa, Milena Sitkiewicz, Marcin Landwójtowicz, Tomasz Wróbel, Maciej Tomasiewicz, Anna Czyż
    Journal of Clinical Medicine.2024; 13(19): 5987.     CrossRef
  • circAGO3 facilitates NF-κB pathway-mediated inflammatory atrophy in chicken skeletal muscle via the miR-34b-5p/TRAF3 axis
    Xiyu Zhao, Shuyue Tang, Zhenyu Lei, Xiaoxu Shen, Yao Zhang, Shunshun Han, Huadong Yin, Can Cui
    International Journal of Biological Macromolecules.2024; 283: 137614.     CrossRef
  • Analyzing body composition in living kidney donors: impact on post-transplant kidney function
    Evelien E. Quint, Lisa B. Westenberg, Gertrude J. Nieuwenhuijs-Moeke, Eva A. N. van den Broek, Marcel Zorgdrager, Alain R. Viddeleer, Stephan J. L. Bakker, Ija M. Nolte, Marco van Londen, Robert A. Pol
    Frontiers in Nephrology.2024;[Epub]     CrossRef
  • Eccentric Resistance Exercise Effects on Older Adults With Metabolic Syndrome
    Wafina Rohadhia, Christine Kudiarasu, Tomoko Koeda, Yoshihiro Katsura, Kazunori Nosaka, Favil Singh
    Journal of Clinical Exercise Physiology.2024; 13(4): 129.     CrossRef
  • Prevalence of adiposity-based chronic disease and its association with anthropometric and clinical indices: a cross-sectional study
    Luis E González-Salazar, Aurora E Serralde-Zúñiga, Adriana Flores-López, Juan P Díaz-Sánchez, Isabel Medina-Vera, Edgar Pichardo-Ontiveros, Rocío Guizar-Heredia, Karla G Hernández-Gómez, Ana Vigil-Martínez, Liliana Arteaga-Sánchez, Azalia Avila-Nava, Nata
    British Journal of Nutrition.2023; 130(1): 93.     CrossRef
  • Skeletal Muscle Myokine Expression in Critical Illness, Association With Outcome and Impact of Therapeutic Interventions
    Ilse Vanhorebeek, Jan Gunst, Michaël P Casaer, Inge Derese, Sarah Derde, Lies Pauwels, Johan Segers, Greet Hermans, Rik Gosselink, Greet Van den Berghe
    Journal of the Endocrine Society.2023;[Epub]     CrossRef
  • Effect of Circadian Rhythm Disturbance on the Human Musculoskeletal System and the Importance of Nutritional Strategies
    Norsham Juliana, Liyana Azmi, Nadia Mohd Effendy, Nur Islami Mohd Fahmi Teng, Izuddin Fahmy Abu, Nur Nabilah Abu Bakar, Sahar Azmani, Noor Anisah Abu Yazit, Suhaini Kadiman, Srijit Das
    Nutrients.2023; 15(3): 734.     CrossRef
  • Molecular mechanisms of post‐burn muscle wasting and the therapeutic potential of physical exercise
    Dorien Dombrecht, Ulrike Van Daele, Birgit Van Asbroeck, David Schieffelers, Pieter‐Jan Guns, Nick Gebruers, Jill Meirte, Eric van Breda
    Journal of Cachexia, Sarcopenia and Muscle.2023; 14(2): 758.     CrossRef
  • Metabolic Impact of Frailty Changes Diabetes Trajectory
    Alan J. Sinclair, Ahmed H. Abdelhafiz
    Metabolites.2023; 13(2): 295.     CrossRef
  • From Single- to Multi-organ-on-a-Chip System for Studying Metabolic Diseases
    Minjeong Jang, Hong Nam Kim
    BioChip Journal.2023; 17(2): 133.     CrossRef
  • INFLUENCE OF SARCOPENIA ON THE COURSE AND PROGNOSIS IN PATIENTS WITH CHRONIC HEART FAILURE
    Gulyaev N.I., Adamov A.A., Akhmetshin I.M.
    "Medical & pharmaceutical journal "Pulse".2023; : 124.     CrossRef
  • Frailty and the Interactions between Skeletal Muscle, Bone, and Adipose Tissue-Impact on Cardiovascular Disease and Possible Therapeutic Measures
    María Elena Soto, Israel Pérez-Torres, María Esther Rubio-Ruiz, Agustina Cano-Martínez, Linaloe Manzano-Pech, Verónica Guarner-Lans
    International Journal of Molecular Sciences.2023; 24(5): 4534.     CrossRef
  • Sarcoplasmic Reticulum Ca2+ Buffer Proteins: A Focus on the Yet-To-Be-Explored Role of Sarcalumenin in Skeletal Muscle Health and Disease
    Elena Conte, Giorgia Dinoi, Paola Imbrici, Annamaria De Luca, Antonella Liantonio
    Cells.2023; 12(5): 715.     CrossRef
  • Antarctic krill extracts enhance muscle regeneration and muscle function via mammalian target of rapamycin regulation
    Seongmin Lee, Mi-Ock Baek, Sana Abdul Khaliq, Amna Parveen, Sun Yeou Kim, Jin-Hyoung Kim, Il-Chan Kim, Mee-Sup Yoon
    Journal of Functional Foods.2023; 103: 105483.     CrossRef
  • Pharmacological and physiological roles of adipokines and myokines in metabolic-related dementia
    Archana Arjunan, Juhyun Song
    Biomedicine & Pharmacotherapy.2023; 163: 114847.     CrossRef
  • PRMT5 links lipid metabolism to contractile function of skeletal muscles
    Kun Ho Kim, Zhihao Jia, Madigan Snyder, Jingjuan Chen, Jiamin Qiu, Stephanie N Oprescu, Xiyue Chen, Sabriya A Syed, Feng Yue, Bruno T Roseguini, Anthony N Imbalzano, Changdeng Hu, Shihuan Kuang
    EMBO reports.2023;[Epub]     CrossRef
  • “Biqi” Bayberry Extract Promotes Skeletal Muscle Fiber Type Remodeling by Increasing Fast Myofiber Formation via the Akt/FoxO1 Pathway in Mice
    Jinjie Li, Yi Li, Xiangying Suo, Jiangtao Li, Da Huang, Guangning Kou
    Foods.2023; 12(13): 2471.     CrossRef
  • Effects of high-intensity interval training (HIIT) on skeletal muscle atrophy, function, and myokine profile in diabetic myopathy
    Yeşim Özçatal, Fırat Akat, Yakup Tatar, Hakan Fıçıcılar, Bilge Serdaroğlu, Ferda Topal Çelikkan, Metin Baştuğ
    Cytokine.2023; 169: 156279.     CrossRef
  • Impaired proteostatic mechanisms other than decreased protein synthesis limit old skeletal muscle recovery after disuse atrophy
    Jordan D. Fuqua, Marcus M. Lawrence, Zachary R. Hettinger, Agnieszka K. Borowik, Parker L. Brecheen, Marcelina M. Szczygiel, Claire B. Abbott, Frederick F. Peelor, Amy L. Confides, Michael Kinter, Sue C. Bodine, Esther E. Dupont‐Versteegden, Benjamin F. M
    Journal of Cachexia, Sarcopenia and Muscle.2023; 14(5): 2076.     CrossRef
  • Body physique rating as a factor to identify at-risk Mexicans for Metabolic Syndrome
    Oscar Herrera-Fomperosa, Sergio K. Bustamante-Villagomez, Sarahí Vazquez-Álvarez, Gabriela Vázquez-Marroquín, Leonardo M. Porchia, Enrique Torres-Rasgado, Ricardo Pérez-Fuentes, M. Elba Gonzalez-Mejia
    Human Nutrition & Metabolism.2023; 33: 200206.     CrossRef
  • Association between Fractional Oxygen Extraction from Resting Quadriceps Muscle and Body Composition in Healthy Men
    Rodrigo Yáñez-Sepúlveda, Jorge Olivares-Arancibia, Guillermo Cortés-Roco, Aldo Vasquez-Bonilla, Matías Monsalves-Álvarez, Ildefonso Alvear-Órdenes, Marcelo Tuesta
    Journal of Functional Morphology and Kinesiology.2023; 8(4): 149.     CrossRef
  • Correlations between Mental Health, Physical Activity, and Body Composition in American College Students after the COVID-19 Pandemic Lockdown
    Luis Torres, Manuela C. Caciula, Alin S. Tomoiaga, Carmen Gugu-Gramatopol
    International Journal of Environmental Research and Public Health.2023; 20(22): 7045.     CrossRef
  • Association between total body muscle percentage and prevalence of non-alcoholic fatty liver disease in Korean adults findings from an 18-year follow-up: a prospective cohort study
    Byoung Chan Ahn, Chul Yong Park, Jung Hee Hong, Ki Ook Baek
    Journal of Yeungnam Medical Science.2023; 40(Suppl): S47.     CrossRef
  • The independent and joint associations among muscle strength, abdominal obesity and cardiometabolic variables among adults
    Tiago Rodrigues de Lima, David Alejandro González‐Chica, Xuemei Sui, Diego Augusto Santos Silva
    European Journal of Sport Science.2022; 22(7): 1122.     CrossRef
  • Mentale Gesundheit und physische Aktivität
    Wolfgang Laube
    Manuelle Medizin.2022; 60(1): 13.     CrossRef
  • A new paradigm in sarcopenia: Cognitive impairment caused by imbalanced myokine secretion and vascular dysfunction
    Danbi Jo, Gwangho Yoon, Oh Yoen Kim, Juhyun Song
    Biomedicine & Pharmacotherapy.2022; 147: 112636.     CrossRef
  • Sarcopenia Is a Cause and Consequence of Metabolic Dysregulation in Aging Humans: Effects of Gut Dysbiosis, Glucose Dysregulation, Diet and Lifestyle
    James W. Daily, Sunmin Park
    Cells.2022; 11(3): 338.     CrossRef
  • Leveraging deep phenotyping from health check-up cohort with 10,000 Korean individuals for phenome-wide association study of 136 traits
    Eun Kyung Choe, Manu Shivakumar, Anurag Verma, Shefali Setia Verma, Seung Ho Choi, Joo Sung Kim, Dokyoon Kim
    Scientific Reports.2022;[Epub]     CrossRef
  • Zika virus disrupts gene expression in human myoblasts and myotubes: Relationship with susceptibility to infection
    Ingo Riederer, Daniella Arêas Mendes-da-Cruz, Guilherme Cordenonsi da Fonseca, Mariela Natacha González, Otavio Brustolini, Cássia Rocha, Guilherme Loss, Joseane Biso de Carvalho, Mariane Talon Menezes, Lidiane Menezes Souza Raphael, Alexandra Gerber, Myr
    PLOS Neglected Tropical Diseases.2022; 16(2): e0010166.     CrossRef
  • Teil 1: Muskeldysfunktionen – mit Training gegen Schmerz
    Wolfgang Laube
    Manuelle Medizin.2022; 60(2): 84.     CrossRef
  • Transcription factors KLF15 and PPARδ cooperatively orchestrate genome-wide regulation of lipid metabolism in skeletal muscle
    Liyan Fan, David R. Sweet, Erica K. Fan, Domenick A. Prosdocimo, Annmarie Madera, Zhen Jiang, Roshan Padmanabhan, Saptarsi M. Haldar, Vinesh Vinayachandran, Mukesh K. Jain
    Journal of Biological Chemistry.2022; 298(6): 101926.     CrossRef
  • An Overview of the TRP-Oxidative Stress Axis in Metabolic Syndrome: Insights for Novel Therapeutic Approaches
    Mizael C. Araújo, Suzany H. S. Soczek, Jaqueline P. Pontes, Leonardo A. C. Marques, Gabriela S. Santos, Gisele Simão, Laryssa R. Bueno, Daniele Maria-Ferreira, Marcelo N. Muscará, Elizabeth S. Fernandes
    Cells.2022; 11(8): 1292.     CrossRef
  • Effects of a 10-Week Physical Activity Intervention on Asylum Seekers’ Physiological Health
    Matheus Guerra, Danilo Garcia, Maryam Kazemitabar, Erik Lindskär, Erica Schütz, Daniel Berglind
    Brain Sciences.2022; 12(7): 822.     CrossRef
  • Low muscle mass and mortality risk later in life: A 10-year follow-up study
    Cristina Camargo Pereira, Valéria Pagotto, Cesar de Oliveira, Erika Aparecida Silveira, Kiyoshi Sanada
    PLOS ONE.2022; 17(7): e0271579.     CrossRef
  • Independent and joint associations of weightlifting and aerobic activity with all-cause, cardiovascular disease and cancer mortality in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
    Jessica Gorzelitz, Britton Trabert, Hormuzd A Katki, Steven C Moore, Eleanor L Watts, Charles E Matthews
    British Journal of Sports Medicine.2022; 56(22): 1277.     CrossRef
  • Handgrip Strength Cutoff Value Among Korean Adolescents with Metabolic Syndrome Components: Korean National Health and Nutrition Examination Survey Data 2014–2017
    Chang Hoon Lee, Jun Hyeok Lee, Yong Whi Jeong, Hong Koh, Yunkoo Kang
    Metabolic Syndrome and Related Disorders.2022; 20(10): 584.     CrossRef
  • Physical activity level, sitting time, and skeletal muscle mass between esports players and non-esports players
    Zhi H. SEE, Mohamad S. ABDUL HAMID
    Gazzetta Medica Italiana Archivio per le Scienze Mediche.2022;[Epub]     CrossRef
  • Impact of the Nutrition–Inflammation Status on the Functionality of Patients with Chronic Kidney Disease
    Ángel Nogueira, Graciela Álvarez, Guillermina Barril
    Nutrients.2022; 14(22): 4745.     CrossRef
  • Does Timing Matter? A Narrative Review of Intermittent Fasting Variants and Their Effects on Bodyweight and Body Composition
    Alan A. Aragon, Brad J. Schoenfeld
    Nutrients.2022; 14(23): 5022.     CrossRef
  • Sex- and region-specific associations of skeletal muscle mass with metabolic dysfunction-associated fatty liver disease
    Pei Xiao, Pu Liang, Panjun Gao, Jinyi Wu
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Donor Skeletal Muscle Quality Affects Graft Mortality After Living Donor Liver Transplantation- A Single Center, Retrospective Study
    Takahiro Tomiyama, Noboru Harada, Takeo Toshima, Yuki Nakayama, Katsuya Toshida, Akinari Morinaga, Yukiko Kosai-Fujimoto, Takahiro Tomino, Takeshi Kurihara, Kazuki Takeishi, Yoshihiro Nagao, Kazutoyo Morita, Shinji Itoh, Tomoharu Yoshizumi
    Transplant International.2022;[Epub]     CrossRef
  • Handgrip Strength Is Associated with Metabolic Syndrome and Insulin Resistance in Children and Adolescents: Analysis of Korea National Health and Nutrition Examination Survey 2014–2018
    Hae Woon Jung, Jieun Lee, Jaehyun Kim
    Journal of Obesity & Metabolic Syndrome.2022; 31(4): 334.     CrossRef
  • Diet quality and a traditional dietary pattern predict lean mass in Australian women: Longitudinal data from the Geelong Osteoporosis Study
    Jessica A. Davis, Mohammadreza Mohebbi, Fiona Collier, Amy Loughman, Nitin Shivappa, James R. Hébert, Julie A. Pasco, Felice N. Jacka
    Preventive Medicine Reports.2021; 21: 101316.     CrossRef
  • Association between serum FGF21 level and sarcopenia in older adults
    Hee-Won Jung, Jin Hoon Park, Da Ae Kim, Il-Young Jang, So Jeong Park, Jin Young Lee, Seungjoo Lee, Jeoung Hee Kim, Hyon-Seung Yi, Eunju Lee, Beom-Jun Kim
    Bone.2021; 145: 115877.     CrossRef
  • Benchside to the bedside of frailty and cardiovascular aging: Main shared cellular and molecular mechanisms
    Sandra Maria Barbalho, Ricardo José Tofano, Eduardo Federigui Baisi Chagas, Cláudia Rucco Penteado Detregiachi, Ricardo de Alvares Goulart, Uri Arian Princ Flato
    Experimental Gerontology.2021; 148: 111302.     CrossRef
  • Effect of CCL11 on In Vitro Myogenesis and Its Clinical Relevance for Sarcopenia in Older Adults
    Da Ae Kim, So Jeong Park, Jin Young Lee, Jeoung Hee Kim, Seungjoo Lee, Eunju Lee, Il-Young Jang, Hee-Won Jung, Jin Hoon Park, Beom-Jun Kim
    Endocrinology and Metabolism.2021; 36(2): 455.     CrossRef
  • Sarcopenic obesity as a determinant of cardiovascular disease risk in older people: a systematic review
    Katherine Evans, Dima Abdelhafiz, Ahmed H Abdelhafiz
    Postgraduate Medicine.2021; 133(8): 831.     CrossRef
  • Decreased continuous sitting time increases heart rate variability in patients with cardiovascular risk factors
    Natsuki Nakayama, Masahiko Miyachi, Koji Tamakoshi, Toshio Hayashi, Koji Negi, Koji Watanabe, Makoto Hirai, Sharon Mary Brownie
    PLOS ONE.2021; 16(6): e0253399.     CrossRef
  • Muskeltraining – ein universelles Medikament
    Wolfgang Laube
    Manuelle Medizin.2021; 59(3): 179.     CrossRef
  • The Effects of Oxytocin on Appetite Regulation, Food Intake and Metabolism in Humans
    Liya Kerem, Elizabeth A. Lawson
    International Journal of Molecular Sciences.2021; 22(14): 7737.     CrossRef
  • Weight Loss Strategies and the Risk of Skeletal Muscle Mass Loss
    David McCarthy, Aloys Berg
    Nutrients.2021; 13(7): 2473.     CrossRef
  • Association of FGF‐19 and FGF‐21 levels with primary sarcopenia
    Rabia Bag Soytas, Veysel Suzan, Pinar Arman, Tugce Emiroglu Gedik, Damla Unal, Mahir Cengiz, Ibrahim Murat Bolayirli, Deniz Suna Erdincler, Alper Doventas, Hakan Yavuzer
    Geriatrics & Gerontology International.2021; 21(10): 959.     CrossRef
  • Der Muskulatur mehr Aufmerksamkeit schenken!
    Wolfgang Laube
    Manuelle Medizin.2021; 59(4): 302.     CrossRef
  • Methodology, clinical applications, and future directions of body composition analysis using computed tomography (CT) images: A review
    Antti Tolonen, Tomppa Pakarinen, Antti Sassi, Jere Kyttä, William Cancino, Irina Rinta-Kiikka, Said Pertuz, Otso Arponen
    European Journal of Radiology.2021; 145: 109943.     CrossRef
  • Waist and hip circumference are independently associated with the risk of liver disease in population‐based studies
    Oscar Danielsson, Markku J. Nissinen, Antti Jula, Veikko Salomaa, Satu Männistö, Annamari Lundqvist, Markus Perola, Fredrik Åberg
    Liver International.2021; 41(12): 2903.     CrossRef
  • Understanding of sarcopenia: from definition to therapeutic strategies
    Jee Won Kim, Ryuni Kim, Hyerim Choi, Sang-Jin Lee, Gyu-Un Bae
    Archives of Pharmacal Research.2021; 44(9-10): 876.     CrossRef
  • Muscle strength and its association with cardiometabolic variables in adolescents: does the expression of muscle strength values matter?
    Tiago Rodrigues de Lima, Xuemei Sui, Luiz Rodrigo Augustemak de Lima, Diego Augusto Santos Silva
    World Journal of Pediatrics.2021; 17(6): 597.     CrossRef
  • Musclin Is Related to Insulin Resistance and Body Composition, but Not to Body Mass Index or Cardiorespiratory Capacity in Adults
    Yeliana L. Sánchez, Manuela Yepes-Calderón, Luis Valbuena, Andrés F. Milán, María C. Trillos-Almanza, Sergio Granados, Miguel Peña, Mauricio Estrada-Castrillón, Juan C. Aristizábal, Raúl Narvez-Sanchez, Jaime Gallo-Villegas, Juan C. Calderón
    Endocrinology and Metabolism.2021; 36(5): 1055.     CrossRef
  • Physical Exercise and Myokines: Relationships with Sarcopenia and Cardiovascular Complications
    Sandra Maria Barbalho, Uri Adrian Prync Flato, Ricardo José Tofano, Ricardo de Alvares Goulart, Elen Landgraf Guiguer, Cláudia Rucco P. Detregiachi, Daniela Vieira Buchaim, Adriano Cressoni Araújo, Rogério Leone Buchaim, Fábio Tadeu Rodrigues Reina, Piero
    International Journal of Molecular Sciences.2020; 21(10): 3607.     CrossRef
  • Prevalence of Metabolic Syndrome and Association with Grip Strength in Older Adults: Findings from the HOPE Study


    Reshma Aziz Merchant, Yiong Huak Chan, Jia Yi Lim, John E Morley
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 2677.     CrossRef
  • Lower Serum n-3 Fatty Acid Level in Older Adults with Sarcopenia
    Il-Young Jang, Hee-Won Jung, Jin Hoon Park, Jeoung Hee Kim, Seungjoo Lee, Eunju Lee, Jin Young Lee, So Jeong Park, Da Ae Kim, Su Jung Kim, Hyun Ju Yoo, Beom-Jun Kim
    Nutrients.2020; 12(10): 2959.     CrossRef
  • Advances in understanding of health‐promoting benefits of medicine and food homology using analysis of gut microbiota and metabolomics
    Minmin Yang, Tao Yan, Meng Yu, Jie Kang, Ruoxi Gao, Peng Wang, Yuhuan Zhang, Huafeng Zhang, Lin Shi
    Food Frontiers.2020; 1(4): 398.     CrossRef
  • The association of circulating kynurenine, a tryptophan metabolite, with frailty in older adults
    Il-Young Jang, Jin Hoon Park, Jeoung Hee Kim, Seungjoo Lee, Eunju Lee, Jin Young Lee, So Jeong Park, Da Ae Kim, Mark W. Hamrick, Beom-Jun Kim
    Aging.2020; 12(21): 22253.     CrossRef
  • Sarcopenia and Muscle Aging: A Brief Overview
    Tam Dao, Alexander E. Green, Yun A Kim, Sung-Jin Bae, Ki-Tae Ha, Karim Gariani, Mi-ra Lee, Keir J. Menzies, Dongryeol Ryu
    Endocrinology and Metabolism.2020; 35(4): 716.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism
TOP